U.S. patent application number 12/436665 was filed with the patent office on 2009-11-26 for heterocyclic derivatives and their use as therapeutic agents.
This patent application is currently assigned to Xenon Pharmaceuticals Inc.. Invention is credited to Nagasree Chakka, Jian-min Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Kashinath Sadalapure, Shaoyi Sun.
Application Number | 20090291957 12/436665 |
Document ID | / |
Family ID | 35623357 |
Filed Date | 2009-11-26 |
United States Patent
Application |
20090291957 |
Kind Code |
A1 |
Kamboj; Rajender ; et
al. |
November 26, 2009 |
HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
Abstract
Methods of treating an SCD-mediated disease or condition in a
mammal, preferably a human, are disclosed, wherein the methods
comprise, for example, administering to a mammal in need thereof a
compound of formula (II): ##STR00001## where x, y, A, D, E, T, Q,
G, Z, J, K, L, M, W, V, R.sup.2, R.sup.3, R.sup.5, R.sup.5a,
R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a are
defined herein. Pharmaceutical compositions comprising the
compounds of formula (II) are also disclosed.
Inventors: |
Kamboj; Rajender; (Burnaby,
CA) ; Fu; Jian-min; (Coquitlam, CA) ;
Kodumuru; Vishnumurthy; (Burnaby, CA) ; Liu;
Shifeng; (Port Coquitlam, CA) ; Sadalapure;
Kashinath; (Edmonton, CA) ; Chakka; Nagasree;
(Burnaby, CA) ; Hou; Duanjie; (Burnaby, CA)
; Sun; Shaoyi; (Coquitlam, CA) |
Correspondence
Address: |
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE, SUITE 5400
SEATTLE
WA
98104
US
|
Assignee: |
Xenon Pharmaceuticals Inc.
Burnaby
CA
|
Family ID: |
35623357 |
Appl. No.: |
12/436665 |
Filed: |
May 6, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11575643 |
Mar 20, 2007 |
7547698 |
|
|
PCT/US2005/033738 |
Sep 20, 2005 |
|
|
|
12436665 |
|
|
|
|
60611646 |
Sep 20, 2004 |
|
|
|
Current U.S.
Class: |
514/248 ;
435/184; 514/254.06; 544/236; 544/370 |
Current CPC
Class: |
A61P 3/00 20180101; A61P
1/16 20180101; A61P 1/18 20180101; A61P 9/12 20180101; A61P 27/02
20180101; A61P 19/02 20180101; A61P 19/06 20180101; A61P 17/04
20180101; A61P 31/12 20180101; A61P 21/00 20180101; A61P 25/00
20180101; A61P 3/06 20180101; A61P 9/04 20180101; A61P 9/10
20180101; A61P 17/10 20180101; A61P 7/02 20180101; A61P 11/06
20180101; C07D 487/04 20130101; A61K 31/497 20130101; A61P 37/02
20180101; A61P 25/18 20180101; A61P 17/06 20180101; A61P 43/00
20180101; A61P 9/00 20180101; A61P 29/00 20180101; A61P 31/20
20180101; A61K 31/50 20130101; A61P 3/04 20180101; A61P 31/16
20180101; A61P 15/08 20180101; A61P 31/14 20180101; A61P 35/04
20180101; A61P 3/10 20180101; C07D 235/08 20130101; A61P 35/00
20180101 |
Class at
Publication: |
514/248 ;
544/236; 435/184; 544/370; 514/254.06 |
International
Class: |
A61K 31/5025 20060101
A61K031/5025; C07D 487/02 20060101 C07D487/02; C12N 9/99 20060101
C12N009/99; C07D 403/02 20060101 C07D403/02; A61K 31/496 20060101
A61K031/496; A61P 9/00 20060101 A61P009/00; A61P 3/00 20060101
A61P003/00 |
Claims
1. A compound of formula (II): ##STR00010## x and y are each
independently 1, 2 or 3; J and K are each independently N or
C(R.sup.11); A and E are each independently N or NH; D, T and Q are
each independently C; G, Z, L and M are each independently
C(R.sup.4); W is a direct bond, --N(R.sup.1)C(O)--,
--C(O)N(R.sup.1)--, --OC(O)N(R.sup.1)--,
--N(R.sup.1)C(O)N(R.sup.1)--, --O--, --N(R.sup.1)--, --S(O).sub.t--
(where t is 0, 1 or 2), --N(R.sup.1)S(O).sub.p-- (where p is 1 or
2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl; or
R.sup.2 is a multi-ring structure having 2 to 4 rings wherein the
rings are independently selected from the group consisting of
cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all
of the rings may be fused to each other; R.sup.3 is selected from
the group consisting of C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.2-C.sub.12hydroxyalkenyl, C.sub.2-C.sub.12alkoxyalkyl,
C.sub.3-C.sub.12cycloalkyl, C.sub.4-C.sub.12cycloalkylalkyl, aryl,
C.sub.7-C.sub.19aralkyl, C.sub.3-C.sub.12heterocyclyl,
C.sub.3-C.sub.12heterocyclylalkyl, C.sub.1-C.sub.12heteroaryl and
C.sub.3-C.sub.12heteroarylalkyl; or R.sup.3 is a multi-ring
structure having 2 to 4 rings wherein the rings are independently
selected from the group consisting of cycloalkyl, heterocyclyl,
aryl and heteroaryl and where some or all of the rings may be fused
to each other; each R.sup.4 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl,
C.sub.1-C.sub.12alkoxy, haloalkyl, cyano, nitro or
--N(R.sup.9).sub.2; R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7,
R.sup.7a, R.sup.8 and R.sup.8a are each independently selected from
hydrogen or C.sub.1-C.sub.3alkyl; or R.sup.5 and R.sup.5a,
together, R.sup.6 and R.sup.6a together, or R.sup.7 and R.sup.7a
together, or R.sup.8 and R.sup.8a, together are an oxo group,
provided that when V is --C(O)--, R.sup.6 and R.sup.6a, together or
R.sup.8 and R.sup.8a together do not form an oxo group, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; or one of R.sup.5, R.sup.5a, or R.sup.6
and R.sup.6a together with one of R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a forms a direct bond or an alkylene bridge, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8, and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; each R.sup.9 is independently selected
from hydrogen or C.sub.1-C.sub.6alkyl; R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl; and R.sup.11 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl or
C.sub.1-C.sub.12alkoxy; as a stereoisomer, enantiomer or tautomer
thereof, as a mixture of stereoisomers, as a pharmaceutically
acceptable salt thereof, or as a prodrug thereof.
2. The compound of claim 1 wherein the compound of formula (II) is
a compound of the following formula (IIa): ##STR00011## wherein: x
and y are each independently 1, 2 or 3; W is a direct bond,
--N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--, --OC(O)N(R.sup.1)--,
--N(R.sup.1)C(O)N(R.sup.1)--, --O--, --N(R.sup.1)--, --S(O).sub.t--
(where t is 0, 1 or 2), --N(R.sup.1)S(O).sub.p-- (where p is 1 or
2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl; or
R.sup.2 is a multi-ring structure having 2 to 4 rings wherein the
rings are independently selected from the group consisting of
cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all
of the rings may be fused to each other; R.sup.3 is selected from
the group consisting of C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.2-C.sub.12hydroxyalkenyl, C.sub.2-C.sub.12alkoxyalkyl,
C.sub.3-C.sub.12cycloalkyl, C.sub.4-C.sub.12cycloalkylalkyl, aryl,
C.sub.7-C.sub.19aralkyl, C.sub.3-C.sub.12heterocyclyl,
C.sub.3-C.sub.12heterocyclylalkyl, C.sub.1-C.sub.12heteroaryl and
C.sub.3-C.sub.12heteroarylalkyl; or R.sup.3 is a multi-ring
structure having 2 to 4 rings wherein the rings are independently
selected from the group consisting of cycloalkyl, heterocyclyl,
aryl and heteroaryl and where some or all of the rings may be fused
to each other; R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7,
R.sup.7a, R.sup.8 and R.sup.8a are each independently selected from
hydrogen or C.sub.1-C.sub.3alkyl; or R.sup.5 and R.sup.5a together,
or R.sup.6 and R.sup.6a together, or R.sup.7 and R.sup.7a together,
or R.sup.8 and R.sup.8a together are an oxo group, provided that
when V is --C(O)--, R.sup.6 and R.sup.6a together or R.sup.8 and
R.sup.8a together do not form an oxo group, while the remaining
R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8
and R.sup.8a are each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl; or one of R.sup.5, R.sup.5a, R.sup.6 and
R.sup.6a together with one of R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a forms a direct bond or an alkylene bridge, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8, and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; and R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl.
3. The compound of claim 2 wherein: x and y are each 1; W is a
direct bond, --N(R.sup.1)C(O)--, or --C(O)N(R.sup.1)--; V is
--C(O)--; each R.sup.1 is independently selected from the group
consisting of hydrogen, C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.4-C.sub.12cycloalkylalkyl and
C.sub.7-C.sub.19aralkyl; R.sup.2 is selected from the group
consisting of C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl;
R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl; and
R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8
and R.sup.8a are each hydrogen.
4. The compound of claim 3 selected from the group consisting of
the following:
[4-(2-Propyl-1H-benzoimidazol-5-yl)piperazin-1-yl](2-trifluoromethylpheny-
l)methanone; and
[4-(2-Pentyl-1H-benzoimidazol-5-yl)piperazin-1-yl](2-trifluoromethylpheny-
l)methanone.
5. A method of inhibiting human stearoyl-CoA desaturase (hSCD)
activity comprising contacting a source of hSCD with a compound of
formula (II): ##STR00012## x and y are each independently 1, 2 or
3; J and K are each independently N or C(R.sup.11); A and E are
each independently N or NH; D, T and Q are each independently C; G,
Z, L and M are each independently C(R.sup.4); W is a direct bond,
--N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--, --OC(O)N(R.sup.1)--,
--N(R.sup.1)C(O)N(R.sup.1)--, --O--, --N(R.sup.1)--, --S(O).sub.t--
(where t is 0, 1 or 2), --N(R.sup.1)S(O).sub.p-- (where p is 1 or
2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl; or
R.sup.2 is a multi-ring structure having 2 to 4 rings wherein the
rings are independently selected from the group consisting of
cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all
of the rings may be fused to each other; R.sup.3 is selected from
the group consisting of C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.2-C.sub.12hydroxyalkenyl, C.sub.2-C.sub.12alkoxyalkyl,
C.sub.3-C.sub.12cycloalkyl, C.sub.4-C.sub.12cycloalkylalkyl, aryl,
C.sub.7-C.sub.19aralkyl, C.sub.3-C.sub.12heterocyclyl,
C.sub.3-C.sub.12heterocyclylalkyl, C.sub.1-C.sub.12heteroaryl and
C.sub.3-C.sub.12heteroarylalkyl; or R.sup.3 is a multi-ring
structure having 2 to 4 rings wherein the rings are independently
selected from the group consisting of cycloalkyl, heterocyclyl,
aryl and heteroaryl and where some or all of the rings may be fused
to each other; each R.sup.4 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl,
C.sub.1-C.sub.12alkoxy, haloalkyl, cyano, nitro or
--N(R.sup.9).sub.2; R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7,
R.sup.7a, R.sup.8 and R.sup.8a are each independently selected from
hydrogen or C.sub.1-C.sub.3alkyl; or R.sup.5 and R.sup.5a together,
or R.sup.6 and R.sup.6a, together, or R.sup.7 and R.sup.7a
together, or R.sup.8 and R.sup.8a, together are an oxo group,
provided that when V is --C(O)--, R.sup.6 and R.sup.6a together or
R.sup.8 and R.sup.8a together do not form an oxo group, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; or one of R.sup.5, R.sup.5a, R.sup.6 and
R.sup.6a together with one of R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a forms a direct bond or an alkylene bridge, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8, and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; each R.sup.9 is independently selected
from hydrogen or C.sub.1-C.sub.6alkyl; R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl; and R.sup.11 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl or
C.sub.1-C.sub.12alkoxy; as a stereoisomer, enantiomer or tautomer
thereof, as a mixture of stereoisomers, as a pharmaceutically
acceptable salt thereof, or as a prodrug thereof.
6. A method of treating a disease or condition mediated by
stearoyl-CoA desaturase (SCD) in a mammal, wherein the method
comprises administering to the mammal in need thereof a
therapeutically effective amount of a compound of formula (II):
##STR00013## x and y are each independently 1, 2 or 3; J and K are
each independently N or C(R.sup.11); A and E are each independently
N or NH; D, T and Q are each independently C; G, Z, L and M are
each independently C(R.sup.4); W is a direct bond,
--N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--, --OC(O)N(R.sup.1)--,
--N(R.sup.1)C(O)N(R.sup.1)--, --O--, --N(R.sup.1)--, --S(O).sub.t--
(where t is 0, 1 or 2), --N(R.sup.1)S(O).sub.p-- (where p is 1 or
2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl; or
R.sup.2 is a multi-ring structure having 2 to 4 rings wherein the
rings are independently selected from the group consisting of
cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all
of the rings may be fused to each other; R.sup.3 is selected from
the group consisting of C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.2-C.sub.12hydroxyalkenyl, C.sub.2-C.sub.12alkoxyalkyl,
C.sub.3-C.sub.12cycloalkyl, C.sub.4-C.sub.12cycloalkylalkyl, aryl,
C.sub.7-C.sub.19aralkyl, C.sub.3-C.sub.12heterocyclyl,
C.sub.3-C.sub.12heterocyclylalkyl, C.sub.1-C.sub.12heteroaryl and
C.sub.3-C.sub.12heteroarylalkyl; or R.sup.3 is a multi-ring
structure having 2 to 4 rings wherein the rings are independently
selected from the group consisting of cycloalkyl, heterocyclyl,
aryl and heteroaryl and where some or all of the rings may be fused
to each other; each R.sup.4 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl,
C.sub.1-C.sub.12alkoxy, haloalkyl, cyano, nitro or
--N(R.sup.9).sub.2; R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7,
R.sup.7a, R.sup.8 and R.sup.8a are each independently selected from
hydrogen or C.sub.1-C.sub.3alkyl; or R.sup.5 and R.sup.5a together,
or R.sup.6 and R.sup.6a together, or R.sup.7 and R.sup.7a together,
or R.sup.8 and R.sup.8a together are an oxo group, provided that
when V is --C(O)--, R.sup.6 and R.sup.6a together or R.sup.8 and
R.sup.8a together do not form an oxo group, while the remaining
R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8
and R.sup.8a are each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl; or one of R.sup.5, R.sup.5a, R.sup.6 and
R.sup.6a together with one of R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a forms a direct bond or an alkylene bridge, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8, and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; each R.sup.9 is independently selected
from hydrogen or C.sub.1-C.sub.6alkyl; R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl; and R.sup.11 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl or
C.sub.1-C.sub.12alkoxy; as a stereoisomer, enantiomer or tautomer
thereof, as a mixture of stereoisomers, as a pharmaceutically
acceptable salt thereof, or as a prodrug thereof.
7. A pharmaceutical composition comprising a pharmaceutically
acceptable excipient or carrier and a therapeutically effective
amount of a compound of formula (II): ##STR00014## x and y are each
independently 1, 2 or 3; J and K are each independently N or
C(R.sup.11); A and E are each independently N or NH; D, T and Q are
each independently C; G, Z, L and M are each independently
C(R.sup.4); W is a direct bond, --N(R.sup.1)C(O)--,
--C(O)N(R.sup.1)--, --OC(O)N(R.sup.1)--,
--N(R.sup.1)C(O)N(R.sup.1)--, --O--, --N(R.sup.1)--, --S(O).sub.t--
(where t is 0, 1 or 2), --N(R.sup.1)S(O).sub.p-- (where p is 1 or
2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl; or
R.sup.2 is a multi-ring structure having 2 to 4 rings wherein the
rings are independently selected from the group consisting of
cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all
of the rings may be fused to each other; R.sup.3 is selected from
the group consisting of C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12alkenyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.2-C.sub.12hydroxyalkenyl, C.sub.2-C.sub.12alkoxyalkyl,
C.sub.3-C.sub.12cycloalkyl, C.sub.4-C.sub.12cycloalkylalkyl, aryl,
C.sub.7-C.sub.19aralkyl, C.sub.3-C.sub.12heterocyclyl,
C.sub.3-C.sub.12heterocyclylalkyl, C.sub.1-C.sub.12heteroaryl and
C.sub.3-C.sub.12heteroarylalkyl; or R.sup.3 is a multi-ring
structure having 2 to 4 rings wherein the rings are independently
selected from the group consisting of cycloalkyl, heterocyclyl,
aryl and heteroaryl and where some or all of the rings may be fused
to each other; each R.sup.4 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl,
C.sub.1-C.sub.12alkoxy, haloalkyl, cyano, nitro or
--N(R.sup.9).sub.2; R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7,
R.sup.7a, R.sup.8 and R.sup.8a are each independently selected from
hydrogen or C.sub.1-C.sub.3alkyl; or R.sup.5 and R.sup.5a together,
or R.sup.6 and R.sup.6a together, or R.sup.7 and R.sup.7a together,
or R.sup.8 and R.sup.8a together are an oxo group, provided that
when V is --C(O)--, R.sup.6 and R.sup.6a, together or R.sup.8 and
R.sup.8a together do not form an oxo group, while the remaining
R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8
and R.sup.8a are each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl; or one of R.sup.5, R.sup.5a, R.sup.6 and
R.sup.6a, together with one of R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a forms a direct bond or an alkylene bridge, while the
remaining R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8, and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl; each R.sup.9 is independently selected
from hydrogen or C.sub.1-C.sub.6alkyl; R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl; and R.sup.11 is independently selected from
hydrogen, fluoro, chloro, C.sub.1-C.sub.12alkyl or
C.sub.1-C.sub.12alkoxy; as a stereoisomer, enantiomer or tautomer
thereof, as a mixture of stereoisomers, as a pharmaceutically
acceptable salt thereof, or as a prodrug thereof.
Description
FIELD OF THE INVENTION
[0001] The present invention relates generally to the field of
inhibitors of stearoyl-CoA desaturase, such as heterocyclic
derivatives, and uses for such compounds in treating and/or
preventing various human diseases, including those mediated by
stearoyl-CoA desaturase (SCD) enzymes, preferably SCD1, especially
diseases related to elevated lipid levels, cardiovascular disease,
diabetes, obesity, metabolic syndrome and the like.
BACKGROUND OF THE INVENTION
[0002] Acyl desaturase enzymes catalyze the formation of double
bonds in fatty acids derived from either dietary sources or de novo
synthesis in the liver. Mammals synthesize at least three fatty
acid desaturases of differing chain length specificity that
catalyze the addition of double bonds at the delta-9, delta-6, and
delta-5 positions. Stearoyl-CoA desaturases (SCDs) introduce a
double bond in the C9-C10 position of saturated fatty acids. The
preferred substrates are palmitoyl-CoA (16:0) and stearoyl-CoA
(18:0), which are converted to palmitoleoyl-CoA (16:1) and
oleoyl-CoA (18:1), respectively. The resulting mono-unsaturated
fatty acids are substrates for incorporation into phospholipids,
triglycerides, and cholesteryl esters.
[0003] A number of mammalian SCD genes have been cloned. For
example, two genes have been cloned from rat (SCD1, SCD2) and four
SCD genes have been isolated from mouse (SCD1, 2, 3, and 4). While
the basic biochemical role of SCD has been known in rats and mice
since the 1970's (Jeffcoat, R. et al., Elsevier Science (1984),
Vol. 4, pp. 85-112; de Antueno, R J, Lipids (1993), Vol. 28, No. 4,
pp. 285-290), it has only recently been directly implicated in
human disease processes.
[0004] A single SCD gene, SCD1, has been characterized in humans.
SCD1 is described in Brownlie et al, PCT published patent
application, WO 01/62954, the disclosure of which is hereby
incorporated by reference in its entirety. A second human SCD
isoform has recently been identified, and because it bears little
sequence homology to alternate mouse or rat isoforms it has been
named human SCD5 or hSCD5 (PCT published patent application, WO
02/26944, incorporated herein by reference in its entirety).
[0005] To date, no small-molecule, drug-like compounds are known
that specifically inhibit or modulate SCD activity. Certain
long-chain hydrocarbons have been used historically to study SCD
activity. Known examples include thia-fatty acids, cyclopropenoid
fatty acids, and certain conjugated linoleic acid isomers.
Specifically, cis-12, trans-10 conjugated linoleic acid is believed
to inhibit SCD enzyme activity and reduce the abundance of SCD1
mRNA while cis-9, trans-11 conjugated linoleic acid does not.
Cyclopropenoid fatty acids, such as those found in stercula and
cotton seeds, are also known to inhibit SCD activity. For example,
sterculic acid (8-(2-octylcyclopropenyl)octanoic acid) and malvalic
acid (7-(2-octylcyclopropenyl)heptanoic acid) are C18 and C16
derivatives of sterculoyl and malvaloyl fatty acids, respectively,
having cyclopropene rings at their C9-C10 position. These agents
are believed to inhibit SCD enzymatic activity by direct
interaction with the enzyme, thus inhibiting delta-9 desaturation.
Other agents that may inhibit SCD activity include thia-fatty
acids, such as 9-thiastearic acid (also called 8-nonylthiooctanoic
acid) and other fatty acids with a sulfoxy moiety.
[0006] These known modulators of delta-9 desaturase activity are
not useful for treating the diseases and disorders linked to SCD1
biological activity. None of the known SCD inhibitor compounds are
selective for SCD or delta-9 desaturases, as they also inhibit
other desaturases and enzymes. The thia-fatty acids, conjugated
linoleic acids and cyclopropene fatty acids (malvalic acid and
sterculic acid) are neither useful at reasonable physiological
doses, nor are they specific inhibitors of SCD1 biological
activity, rather they demonstrate cross inhibition of other
desaturases, in particular the delta-5 and delta-6 desaturases by
the cyclopropene fatty acids.
[0007] The absence of small molecule inhibitors of SCD enzyme
activity is a major scientific and medical disappointment because
evidence is now compelling that SCD activity is directly implicated
in common human disease processes: See e.g., Attie, A. D. et al.,
"Relationship between stearoyl-CoA desaturase activity and plasma
triglycerides in human and mouse hypertriglyceridemia", J. Lipid
Res. (2002), Vol. 43, No. 11, pp. 1899-907; Cohen, P. et al., "Role
for stearoyl-CoA desaturase-1 in leptin-mediated weight loss",
Science (2002), Vol. 297, No. 5579, pp. 240-3, Ntambi, J. M. et
al., "Loss of stearoyl-CoA desaturase-1 function protects mice
against adiposity", Proc. Natl. Acad. Sci. USA. (2002), Vol. 99,
No. 7, pp. 11482-6.
[0008] The present invention solves this problem by presenting new
classes of compounds that are useful in modulating SCD activity and
regulating lipid levels, especially plasma lipid levels, and which
are useful in the treatment of SCD-mediated diseases such as
diseases related to dyslipidemia and disorders of lipid metabolism,
especially diseases related to elevated lipid levels,
cardiovascular disease, diabetes, obesity, metabolic syndrome and
the like.
SUMMARY OF THE INVENTION
[0009] The present invention provides heterocyclic derivatives that
modulate the activity of stearoyl-CoA desaturase. Methods of using
such derivatives to modulate the activity of stearoyl-CoA
desaturase and pharmaceutical compositions comprising such
derivatives are also encompassed.
[0010] Accordingly, in one aspect, the invention provides compounds
of formula (I):
##STR00002##
[0011] wherein:
[0012] x and y are each independently 1, 2 or 3;
[0013] J and K are each independently N or C(R.sup.11);
[0014] L is N or C(R.sup.4);
[0015] M is --N.dbd. or --C(R.sup.4).dbd.;
[0016] W is a direct bond, --N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--,
--OC(O)N(R.sup.1)--, --N(R.sup.1)C(O)N(R.sup.1)--, --O--,
--N(R.sup.1)--, --S(O).sub.t-- (where t is 0, 1 or 2),
--N(R.sup.1)S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--;
[0017] V is --N(R.sup.1)--, --N(R.sup.1)C(O)--, --C(O)--,
--C(O)O--, --C(S)--, --C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is
1 or 2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or
--C(R.sup.10)H--;
[0018] each R.sup.1 is independently selected from the group
consisting of hydrogen, C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.4-C.sub.12cycloalkylalkyl and
C.sub.7-C.sub.19aralkyl;
[0019] R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and
C.sub.3-C.sub.12heteroarylalkyl;
[0020] or R.sup.2 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0021] R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl;
[0022] or R.sup.3 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0023] each R.sup.4 is independently selected from hydrogen,
fluoro, chloro, C.sub.1-C.sub.12alkyl, C.sub.1-C.sub.12alkoxy,
haloalkyl, cyano, nitro or --N(R.sup.9).sub.2;
[0024] R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl;
[0025] or R.sup.5 and R.sup.5a together, R.sup.6 and R.sup.6a
together, or R.sup.7 and R.sup.7a, together, or R.sup.8 and
R.sup.8a together are an oxo group, provided that when V is
--C(O)--, R.sup.6 and R.sup.6a together or R.sup.8 and R.sup.8a
together do not form an oxo group, while the remaining R.sup.5,
R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8 and
R.sup.8a are each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl;
[0026] or one of R.sup.5, R.sup.5a, R.sup.6 and R.sup.6a together
with one of R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a forms a direct
bond or an alkylene bridge, while the remaining R.sup.5, R.sup.5a,
R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8, and R.sup.8a are
each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl;
[0027] each R.sup.9 is independently selected from hydrogen or
C.sub.1-C.sub.6alkyl;
[0028] R.sup.10 is hydrogen or C.sub.1-C.sub.3alkyl; and
[0029] R.sup.11 is independently selected from hydrogen, fluoro,
chloro, C.sub.1-C.sub.12alkyl or C.sub.1-C.sub.12alkoxy;
[0030] as a stereoisomer, enantiomer or tautomer thereof, as a
mixture of stereoisomers, as a pharmaceutically acceptable salt
thereof, or as a prodrug thereof.
[0031] In another aspect, the invention provides compounds of
formula (II):
##STR00003##
[0032] wherein:
[0033] x and y are each independently 1, 2 or 3;
[0034] J and K are each independently N or C(R.sup.11);
[0035] A, D, E, G, Z, L, and M are each independently N, NH or
C(R.sup.4);
[0036] T and Q are each independently C or N;
[0037] W is a direct bond, --N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--,
--OC(O)N(R.sup.1)--, --N(R.sup.1)C(O)N(R.sup.1)--, --O--,
--N(R.sup.1)--, --S(O).sub.t-- (where t is 0, 1 or 2),
--N(R.sup.1)S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--;
[0038] V is --N(R.sup.1)--, --N(R.sup.1)C(O)--, --C(O)--,
--C(O)O--, --C(S)--, --C(O).sub.pN(R.sup.1)--, --S(O).sub.p--
(where p is 1 or 2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2),
or --C(R.sup.10)H--; each R.sup.1 is independently selected from
the group consisting of hydrogen, C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.4-C.sub.12cycloalkylalkyl and
C.sub.7-C.sub.19aralkyl;
[0039] R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and
C.sub.3-C.sub.12heteroarylalkyl;
[0040] or R.sup.2 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0041] R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl;
[0042] or R.sup.3 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0043] each R.sup.4 is independently selected from hydrogen,
fluoro, chloro, C.sub.1-C.sub.12alkyl, C.sub.1-C.sub.12alkoxy,
haloalkyl, cyano, nitro or --N(R.sup.9).sub.2;
[0044] R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl;
[0045] or R.sup.5 and R.sup.5a together, R.sup.6 and R.sup.6a
together, or R.sup.7 and R.sup.7a together, or R.sup.8 and R.sup.8a
together are an oxo group, provided that when V is --C(O)--,
R.sup.6 and R.sup.6a together or R.sup.8 and R.sup.8a together do
not form an oxo group, while the remaining R.sup.5, R.sup.5a,
R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a are each
independently selected from hydrogen or C.sub.1-C.sub.3alkyl;
[0046] or one of R.sup.5, R.sup.5a, R.sup.6 and R.sup.6a together
with one of R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a forms a direct
bond or an alkylene bridge, while the remaining R.sup.5, R.sup.5a,
R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8, and R.sup.8a are
each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl;
[0047] each R.sup.9 is independently selected from hydrogen or
C.sub.1-C.sub.6alkyl;
[0048] R.sup.10 is hydrogen or C.sub.1-C.sub.3alkyl; and
[0049] R.sup.11 is independently selected from hydrogen, fluoro,
chloro, C.sub.1-C.sub.12alkyl or C.sub.1-C.sub.12alkoxy;
[0050] as a stereoisomer, enantiomer or tautomer thereof, as a
mixture of stereoisomers, as a pharmaceutically acceptable salt
thereof, or as a prodrug thereof.
[0051] In another aspect, the invention provides methods of
treating an SCD-mediated disease or condition in a mammal,
preferably a human, wherein the methods comprise administering to
the mammal in need thereof a therapeutically effective amount of a
compound of the invention as set forth above.
[0052] In another aspect, the invention provides compounds or
pharmaceutical compositions useful in treating, preventing and/or
diagnosing a disease or condition relating to SCD biological
activity such as the diseases encompassed by cardiovascular
disorders and/or metabolic syndrome (including dyslipidemia,
insulin resistance and obesity).
[0053] In another aspect, the invention provides methods of
preventing or treating a disease or condition related to elevated
lipid levels, such as plasma lipid levels, especially elevated
triglyceride or cholesterol levels, in a patient afflicted with
such elevated levels, comprising administering to said patient a
therapeutically or prophylactically effective amount of a
composition as disclosed herein. The present invention also relates
to novel compounds having therapeutic ability to reduce lipid
levels in an animal, especially triglyceride and cholesterol
levels.
[0054] In another aspect, the invention provides pharmaceutical
compositions comprising the compounds of the invention as set forth
above, and pharmaceutically acceptable excipients. In one
embodiment, the present invention relates to a pharmaceutical
composition comprising a compound of the invention in a
pharmaceutically acceptable carrier and in an amount effective to
modulate triglyceride level, or to treat diseases related to
dyslipidemia and disorders of lipid metabolism, when administered
to an animal, preferably a mammal, most preferably a human patient.
In an embodiment of such composition, the patient has an elevated
lipid level, such as elevated plasma triglycerides or cholesterol,
before administration of said compound and said compound is present
in an amount effective to reduce said lipid level.
[0055] In another aspect, the invention provides methods for
treating a patient for, or protecting a patient from developing, a
disease or condition mediated by stearoyl-CoA desaturase (SCD),
which methods comprise administering to a patient afflicted with
such disease or condition, or at risk of developing such disease or
condition, a therapeutically effective amount of a compound that
inhibits activity of SCD in a patient when administered
thereto.
[0056] In another aspect, the invention provides methods for
treating a range of diseases involving lipid metabolism utilizing
compounds identified by the methods disclosed herein. In accordance
therewith, there is disclosed herein a range of compounds having
said activity, based on a screening assay for identifying, from a
library of test compounds, a therapeutic agent which modulates the
biological activity of said SCD and is useful in treating a human
disorder or condition relating to serum levels of lipids, such as
triglycerides, VLDL, HDL, LDL, and/or total cholesterol.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0057] Certain chemical groups named herein are preceded by a
shorthand notation indicating the total number of carbon atoms that
are to be found in the indicated chemical group. For example;
C.sub.7-C.sub.12alkyl describes an alkyl group, as defined below,
having a total of 7 to 12 carbon atoms, and
C.sub.4-C.sub.12cycloalkylalkyl describes a cycloalkylalkyl group,
as defined below, having a total of 4 to 12 carbon atoms. The total
number of carbons in the shorthand notation does not include
carbons that may exist in substituents of the group described.
[0058] Accordingly, as used in the specification and appended
claims, unless specified to the contrary, the following terms have
the meaning indicated:
[0059] "Methoxy" refers to the --OCH.sub.3 radical.
[0060] "Cyano" refers to the --CN radical.
[0061] "Nitro" refers to the --NO.sub.2 radical.
[0062] "Trifluoromethyl" refers to the --CF.sub.3 radical.
[0063] "Oxo" refers to the .dbd.O substituent.
[0064] "Thioxo" refers to the .dbd.S substituent.
[0065] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, containing
no unsaturation, having from one to twelve carbon atoms, preferably
one to eight carbon atoms or one to six carbon atoms, and which is
attached to the rest of the molecule by a single bond, e.g.,
methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl), and the like. Unless stated
otherwise specifically in the specification, an alkyl group may be
optionally substituted by one of the following groups: alkyl,
alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl,
heterocyclyl, heteroaryl, --OR.sup.14, --OC(O)--R.sup.14,
--N(R.sup.14).sub.2, --C(O)R.sup.14, --C(O)OR.sup.14,
--C(O)N(R.sup.14).sub.2, --N(R.sup.14)C(O)OR.sup.16,
--N(R.sup.14)C(O)R.sup.16, --N(R.sup.14)(S(O).sub.tR.sup.16) (where
t is 1 to 2), --S(O).sub.tOR.sup.16 (where t is 1 to 2),
--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where each
R.sup.14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl,
cycloalkylalkyl, aryl (optionally substituted with one or more
groups selected from halo or haloalkyl), aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R.sup.16
is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,
heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and
where each of the above substituents is unsubstituted unless
otherwise indicated.
[0066] "C.sub.1-C.sub.3alkyl" refers to an alkyl radical as defined
above containing one to three carbon atoms. The
C.sub.1-C.sub.3alkyl radical may be optionally substituted as
defined for an alkyl group.
[0067] "C.sub.1-C.sub.6alkyl" refers to an alkyl radical as defined
above containing one to six carbon atoms. The C.sub.1-C.sub.6alkyl
radical may be optionally substituted as defined for an alkyl
group.
[0068] "C.sub.1-C.sub.12alkyl" refers to an alkyl radical as
defined above containing one to twelve carbon atoms. The
C.sub.1-C.sub.12alkyl radical may be optionally substituted as
defined for an alkyl group.
[0069] "C.sub.2-C.sub.6alkyl" refers to an alkyl radical as defined
above containing two to six carbon atoms. The C.sub.2-C.sub.6alkyl
radical may be optionally substituted as defined for an alkyl
group.
[0070] "C.sub.3-C.sub.6alkyl" refers to an alkyl radical as defined
above containing three to six carbon atoms. The
C.sub.3-C.sub.6alkyl radical may be optionally substituted as
defined for an alkyl group.
[0071] "C.sub.3-C.sub.12alkyl" refers to an alkyl radical as
defined above containing three to twelve carbon atoms. The
C.sub.3-C.sub.12alkyl radical may be optionally substituted as
defined for an alkyl group.
[0072] "C.sub.6-C.sub.12alkyl" refers to an alkyl radical as
defined above containing six to twelve carbon atoms. The
C.sub.6-C.sub.12alkyl radical may be optionally substituted as
defined for an alkyl group.
[0073] "C.sub.7-C.sub.12alkyl" refers to an alkyl radical as
defined above containing seven to twelve carbon atoms. The
C.sub.7-C.sub.12alkyl radical may be optionally substituted as
defined for an alkyl group.
[0074] "Alkenyl" refers to a straight or branched hydrocarbon chain
radical group consisting solely of carbon and hydrogen atoms,
containing at least one double bond, having from two to twelve
carbon atoms, preferably one to eight carbon atoms and which is
attached to the rest of the molecule by a single bond, e.g.,
ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl,
and the like. Unless stated otherwise specifically in the
specification, an alkenyl group may be optionally substituted by
one of the following groups: alkyl, alkenyl, halo, haloalkyl,
haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl,
heteroarylalkyl, --OR.sup.14, --OC(O)--R.sup.14,
--N(R.sup.14).sub.2, --C(O)R.sup.14, --C(O)OR.sup.14,
--C(O)N(R.sup.14).sub.2, --N(R.sup.14)C(O)OR.sup.16,
--N(R.sup.14)C(O)R.sup.16, --N(R.sup.14)(S(O).sub.tR.sup.16) (where
t is 1 to 2), --S(O).sub.tOR.sup.16 (where t is 1 to 2),
--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--S(O).sub.tN(R.sup.4).sub.2 (where t is 1 to 2) where each
R.sup.14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl,
cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl; and each R.sup.16 is alkyl,
haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,
heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and
where each of the above substituents is unsubstituted.
[0075] "C.sub.3-C.sub.12alkenyl" refers to an alkenyl radical as
defined above containing three to 12 carbon atoms. The
C.sub.3-C.sub.12alkenyl radical may be optionally substituted as
defined for an alkenyl group.
[0076] "C.sub.2-C.sub.12alkenyl" refers to an alkenyl radical as
defined above containing two to 12 carbon atoms. The
C.sub.2-C.sub.12alkenyl radical may be optionally substituted as
defined above for an alkenyl group.
[0077] "Alkylene" and "alkylene chain" refer to a straight or
branched divalent hydrocarbon chain, linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, containing no unsaturation and having from one to twelve
carbon atoms, preferably having from one to eight carbons, e.g.,
methylene, ethylene, propylene, n-butylene, and the like. The
alkylene chain may be attached to the rest of the molecule and to
the radical group through one carbon within the chain or through
any two carbons within the chain. The alkylene chain may be
optionally substituted by one of the following groups: alkyl,
alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl,
heterocyclyl, heteroaryl, --OR.sup.14, --OC(O)--R.sup.14,
--N(R.sup.14).sub.2, --C(O)R.sup.14, --C(O)OR.sup.14,
--C(O)N(R.sup.14).sub.2, --N(R.sup.14)C(O)OR.sup.16,
--N(R.sup.14)C(O)R.sup.16, --N(R.sup.14)(S(O).sub.tR.sup.16) (where
t is 1 to 2), --S(O).sub.tOR.sup.16 (where t is 1 to 2),
--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where each
R.sup.14 is independently hydrogen, alkyl, haloalkyl, cycloalkyl,
cycloalkylalkyl, aryl (optionally substituted with one or more
groups selected from halo or haloalkyl), aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R.sup.16
is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl,
heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, and
where each of the above substituents is unsubstituted unless
otherwise indicated.
[0078] "Alkenylene" and "alkenylene chain" refer to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, containing at least one double bond and having from two
to twelve carbon atoms, e.g., ethenylene, propenylene,
n-butenylene, and the like. The alkenylene chain is attached to the
rest of the molecule through a single bond and to the radical group
through a double bond or a single bond. The points of attachment of
the alkenylene chain to the rest of the molecule and to the radical
group can be through one carbon or any two carbons within the
chain. The alkenylene chain may be optionally substituted by one of
the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano,
nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, --OR.sup.14,
--OC(O)--R.sup.14, --N(R.sup.14).sub.2, --C(O)R.sup.14,
--C(O)OR.sup.14, --C(O)N(R.sup.14).sub.2,
--N(R.sup.14)C(O)OR.sup.16, --N(R.sup.14)C(O)R.sup.16,
--N(R.sup.14)(S(O).sub.tR.sup.16) (where t is 1 to 2),
--S(O).sub.tOR.sup.16 (where t is 1 to 2), --S(O).sub.tR.sup.16
(where t is 0 to 2), and --S(O).sub.tN(R.sup.14).sub.2 (where t is
1 to 2) where each R.sup.14 is independently hydrogen, alkyl,
haloalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally
substituted with one or more groups selected from halo or
haloalkyl), aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or
heteroarylalkyl; and each R.sup.16 is alkyl, haloalkyl, cycloalkyl,
cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl,
heteroaryl or heteroarylalkyl, and where each of the above
substituents is unsubstituted unless otherwise indicated.
[0079] "Alkylene bridge" refers to a straight or branched divalent
hydrocarbon bridge, linking two different carbons of the same ring
structure, consisting solely of carbon and hydrogen, containing no
unsaturation and having from one to twelve carbon atoms, preferably
having from one to eight carbons, e.g., methylene, ethylene,
propylene, n-butylene, and the like. The alkylene bridge may link
any two carbons within the ring structure.
[0080] "Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl radical as defined above. The alkyl part of the
alkoxy radical may be optionally substituted as defined above for
an alkyl radical.
[0081] "C.sub.1-C.sub.6alkoxy" refers to an alkoxy radical as
defined above containing one to six carbon atoms. The alkyl part of
the C.sub.1-C.sub.6alkoxy radical may be optionally substituted as
defined above for an alkyl group.
[0082] "C.sub.1-C.sub.12alkoxy" refers to an alkoxy radical as
defined above containing one to twelve carbon atoms. The alkyl part
of the C.sub.1-C.sub.12alkoxy radical may be optionally substituted
as defined above for an alkyl group.
[0083] "C.sub.3-C.sub.12alkoxy" refers to an alkoxy radical as
defined above containing three to twelve carbon atoms. The alkyl
part of the C.sub.3-C.sub.12alkoxy radical may be optionally
substituted as defined above for an alkyl group.
[0084] "Alkoxyalkyl" refers to a radical of the formula
--R.sub.a--O--R.sub.a where each R.sub.a is independently an alkyl
radical as defined above. The oxygen atom may be bonded to any
carbon in either alkyl radical. Each alkyl part of the alkoxyalkyl
radical may be optionally substituted as defined above for an alkyl
group.
[0085] "C.sub.2-C.sub.12alkoxyalkyl" refers to an alkoxyalkyl
radical as defined above containing two to twelve carbon atoms.
Each alkyl part of the C.sub.2-C.sub.12alkoxyalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0086] "C.sub.3alkoxyalkyl" refers to an alkoxyalkyl radical as
defined above containing three carbon atoms. Each alkyl part of the
C.sub.3alkoxyalkyl radical may be optionally substituted as defined
above for an alkyl group.
[0087] "C.sub.3-C.sub.12alkoxyalkyl" refers to an alkoxyalkyl
radical as defined above containing three to twelve carbon atoms.
Each alkyl part of the C.sub.3-C.sub.12alkoxyalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0088] "Alkylsulfonyl" refers to a radical of the formula
--S(O).sub.2R.sub.a where R.sub.a is an alkyl group as defined
above. The alkyl part of the alkylsulfonyl radical may be
optionally substituted as defined above for an alkyl group.
[0089] "C.sub.1-C.sub.6alkylsulfonyl" refers to an alkylsulfonyl
radical as defined above having one to six carbon atoms. The
C.sub.1-C.sub.6alkylsulfonyl group may be optionally substituted as
defined above for an alkylsulfonyl group.
[0090] "Aryl" refers to aromatic monocyclic or multicyclic
hydrocarbon ring system consisting only of hydrogen and carbon and
containing from 6 to 19 carbon atoms, preferably 6 to 10 carbon
atoms, where the ring system may be partially or fully saturated.
Aryl groups include, but are not limited to groups such as
fluorenyl, phenyl and naphthyl. Unless stated otherwise
specifically in the specification, the term "aryl" or the prefix
"ar-" (such as in "aralkyl") is meant to include aryl radicals
optionally substituted by one or more substituents selected from
the group consisting of alkyl, alkenyl, halo, haloalkyl,
haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl,
heteroarylalkyl, --R.sup.15--OR.sup.14,
--R.sup.15--OC(O)--R.sup.14, --R.sup.15--N(R.sup.14).sub.2,
--R.sup.15--C(O)R.sup.14, --R.sup.15--C(O)OR.sup.14,
--R.sup.15--C(O)N(R.sup.14).sub.2,
--R.sup.15--N(R.sup.14)C(O)OR.sup.16,
--R.sup.15--N(R.sup.14)C(O)R.sup.16,
--R.sup.15--N(R.sup.14)(S(O).sub.tR.sup.16) (where t is 1 to 2),
--R.sup.15--S(O).sub.tOR.sup.16 (where t is 1 to 2),
--R.sup.15--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--R.sup.15--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where
each R.sup.14 is independently hydrogen, alkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R.sup.15 is
independently a direct bond or a straight or branched alkylene or
alkenylene chain; and each R.sup.16 is alkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of
the above substituents is unsubstituted.
[0091] "Aralkyl" refers to a radical of the formula
--R.sub.aR.sub.b where R.sub.a is an alkyl radical as defined above
and R.sub.b is one or more aryl radicals as defined above, e.g.,
benzyl, diphenylmethyl and the like. The aryl part of the aralkyl
radical may be optionally substituted as described above for an
aryl group. The alkyl part of the aralkyl radical may be optionally
substituted as defined above for an alkyl group.
[0092] "C.sub.7-C.sub.12aralkyl" refers to an aralkyl group as
defined above containing seven to twelve carbon atoms. The aryl
part of the C.sub.7-C.sub.12aralkyl radical may be optionally
substituted as described above for an aryl group. The alkyl part of
the C.sub.7-C.sub.12aralkyl radical may be optionally substituted
as defined above for an alkyl group.
[0093] "C.sub.7-C.sub.19aralkyl" refers to an aralkyl group as
defined above containing seven to nineteen carbon atoms. The aryl
part of the C.sub.7-C.sub.19aralkyl radical may be optionally
substituted as described above for an aryl group. The alkyl part of
the C.sub.7-C.sub.19aralkyl radical may be optionally substituted
as defined above for an alkyl group.
[0094] "C.sub.13-C.sub.19aralkyl" refers to an aralkyl group as
defined above containing thirteen to nineteen carbon atoms. The
aryl part of the C.sub.13-C.sub.19aralkyl radical may be optionally
substituted as described above for an aryl group. The alkyl part of
the C.sub.13-C.sub.19aralkyl radical may be optionally substituted
as defined above for an alkyl group.
[0095] "Aralkenyl" refers to a radical of the formula
--R.sub.cR.sub.b where R.sub.c is an alkenyl radical as defined
above and R.sub.b is one or more aryl radicals as defined above,
which may be optionally substituted as described above. The aryl
part of the aralkenyl radical may be optionally substituted as
described above for an aryl group. The alkenyl part of the
aralkenyl radical may be optionally substituted as defined above
for an alkenyl group.
[0096] "Aryloxy" refers to a radical of the formula --OR.sub.b
where R.sub.b is an aryl group as defined above. The aryl part of
the aryloxy radical may be optionally substituted as defined
above.
[0097] "Aryl-C.sub.1-C.sub.6alkyl" refers to a radical of the
formula --R.sub.h--R.sub.i where R.sub.h is an unbranched alkyl
radical having one to six carbons and R.sub.i is an aryl group
attached to the terminal carbon of the alkyl radical.
[0098] "Cycloalkyl" refers to a stable non-aromatic monocyclic or
bicyclic hydrocarbon radical consisting solely of carbon and
hydrogen atoms, having from three to fifteen carbon atoms,
preferably having from three to twelve carbon atoms, and which is
saturated or unsaturated and attached to the rest of the molecule
by a single bond, e.g., cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, decalinyl and the like. Unless otherwise stated
specifically in the specification, the term "cycloalkyl" is meant
to include cycloalkyl radicals which are optionally substituted by
one or more substituents selected from the group consisting of
alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl, heteroarylalkyl,
--R.sup.15--OR.sup.14, --R.sup.15--C(O)--R.sup.14,
--R.sup.15--N(R.sup.14).sub.2, --R.sup.15--C(O)R.sup.14,
R.sup.15CO)R.sup.14, --R.sup.15--C(O)N(R.sup.14).sub.2,
--R.sup.15--N(R.sup.14)C(O)OR.sup.16,
--R.sup.15--N(R.sup.14)C(O)R.sup.16,
--R.sup.15--N(R.sup.14)(S(O).sub.tR.sup.16) (where t is 1 to 2),
--R.sup.15--S(O).sub.tOR.sup.16 (where t is 1 to 2),
--R.sup.15--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--R.sup.15--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where
each R.sup.14 is independently hydrogen, alkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R.sup.15 is
independently a direct bond or a straight or branched alkylene or
alkenylene chain; and each R.sup.16 is alkyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of
the above substituents is unsubstituted.
[0099] "C.sub.3-C.sub.6cycloalkyl" refers to a cycloalkyl radical
as defined above having three to six carbon atoms. The
C.sub.3-C.sub.6cycloalkyl radical may be optionally substituted as
defined above for a cycloalkyl group.
[0100] "C.sub.3-C.sub.12cycloalkyl" refers to a cycloalkyl radical
as defined above having three to twelve carbon atoms. The
C.sub.3-C.sub.12cycloalkyl radical may be optionally substituted as
defined above for a cycloalkyl group.
[0101] "Cycloalkylalkyl" refers to a radical of the formula
--R.sub.aR.sub.d where R.sub.a is an alkyl radical as defined above
and R.sub.d is a cycloalkyl radical as defined above. The
cycloalkyl part of the cycloalkyl radical may be optionally
substituted as defined above for an cycloalkyl radical. The alkyl
part of the cycloalkyl radical may be optionally substituted as
defined above for an alkyl radical.
[0102] "C.sub.4-C.sub.12cycloalkylalkyl" refers to a
cycloalkylalkyl radical as defined above having four to twelve
carbon atoms. The C.sub.4-C.sub.12cycloalkylalkyl radical may be
optionally substituted as defined above for a cycloalkylalkyl
group.
[0103] "Halo" refers to bromo, chloro, fluoro or iodo.
[0104] "Haloalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more halo radicals, as defined above,
e.g., trifluoromethyl, difluoromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl,
3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.
The alkyl part of the haloalkyl radical may be optionally
substituted as defined above for an alkyl group.
[0105] "Haloalkenyl" refers to an alkenyl radical, as defined
above, that is substituted by one or more halo radicals, as defined
above, e.g., 2-bromoethenyl, 3-bromoprop-1-enyl, and the like. The
alkenyl part of the haloalkenyl radical may be optionally
substituted as defined above for an alkyl group.
[0106] "Heterocyclyl" refers to a stable 3- to 18-membered
non-aromatic ring radical which consists of carbon atoms and from
one to five heteroatoms selected from the group consisting of
nitrogen, oxygen and sulfur. For purposes of this invention, the
heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or
tetracyclic ring system, which may include fused or bridged ring
systems; and the nitrogen, carbon or sulfur atoms in the
heterocyclyl radical may be optionally oxidized; the nitrogen atom
may be optionally quaternized; and the heterocyclyl radical may be
partially or fully saturated. Examples of such heterocyclyl
radicals include, but are not limited to, dioxolanyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, thiazolidinyl,
tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl,
thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, the term "heterocyclyl" is meant to include
heterocyclyl radicals as defined above which are optionally
substituted by one or more substituents selected from the group
consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano,
oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
--R.sup.15--OR.sup.14, --R.sup.15--OC(O)--R.sup.14,
--R.sup.15--N(R.sup.14).sub.2, --R.sup.15--C(O)R.sup.14,
--R.sup.15--C(O)OR.sup.14, --R.sup.15--C(O)N(R.sup.14).sub.2,
--R.sup.15--N(R.sup.14)C(O)OR.sup.16,
--R.sup.15--N(R.sup.14)C(O)R.sup.16,
--R.sup.15--N(R.sup.14)(S(O).sub.tR.sup.16) (where t is 1 to 2),
--R.sup.15--S(O).sub.tOR.sup.16 (where t is 1 to 2),
--R.sup.15--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--R.sup.15--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where
each R.sup.14 is independently hydrogen, alkyl, alkenyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R.sup.15 is
independently a direct bond or a straight or branched alkylene or
alkenylene chain; and each R.sup.16 is alkyl, alkenyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of
the above substituents is unsubstituted.
[0107] "C.sub.3-C.sub.12heterocyclyl" refers to a heterocyclyl
radical as defined above having three to twelve carbons. The
C.sub.3-C.sub.12heterocyclyl may be optionally substituted as
defined above for a heterocyclyl group.
[0108] "Heterocyclylalkyl" refers to a radical of the formula
--R.sub.aR.sub.e where R.sub.a is an alkyl radical as defined above
and R.sub.e is a heterocyclyl radical as defined above, and if the
heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen
atom. The alkyl part of the heterocyclylalkyl radical may be
optionally substituted as defined above for an alkyl group. The
heterocyclyl part of the heterocyclylalkyl radical may be
optionally substituted as defined above for a heterocyclyl
group.
[0109] "C.sub.3-C.sub.12heterocyclylalkyl" refers to a
heterocyclylalkyl radical as defined above having three to twelve
carbons. The C.sub.3-C.sub.12heterocyclylalkyl radical may be
optionally substituted as defined above for a heterocyclylalkyl
group.
[0110] "Heteroaryl" refers to a 5- to 18-membered aromatic ring
radical which consists of carbon atoms and from one to five
heteroatoms selected from the group consisting of nitrogen, oxygen
and sulfur. For purposes of this invention, the heteroaryl radical
may be a monocyclic, bicyclic, tricyclic or tetracyclic ring
system, which may include fused or bridged ring systems; and the
nitrogen, carbon or sulfur atoms in the heteroaryl radical may be
optionally oxidized; the nitrogen atom may be optionally
quaternized. Examples include, but are not limited to, azepinyl,
acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl,
benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl,
benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl,
benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl),
benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl,
cinnolinyl, dibenzofuranyl, furanyl, furanonyl, isothiazolyl,
imidazolyl, indolyl, indazolyl, isoindolyl, indolinyl,
isoindolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl,
2-oxoazepinyl, oxazolyl, oxiranyl, phenazinyl, phenothiazinyl,
phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl,
pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,
isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl,
triazinyl, and thiophenyl. Unless stated otherwise specifically in
the specification, the term "heteroaryl" is meant to include
heteroaryl radicals as defined above which are optionally
substituted by one or more substituents selected from the group
consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano,
oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl,
--R.sup.15--OR.sup.14, --R.sup.15--OC(O)--R.sup.14,
--R.sup.15--N(R.sup.14).sub.2, --R.sup.15--C(O)R.sup.14,
--R.sup.15--C(O)OR.sup.14, --R.sup.15--C(O)N(R.sup.14).sub.2,
--R.sup.15--N(R.sup.14)C(O)OR.sup.16,
--R.sup.15--N(R.sup.14)C(O)R.sup.16,
--R.sup.15--N(R.sup.14)(S(O).sub.tR.sup.16) (where t is 1 to 2),
--R.sup.15--S(O).sub.tOR.sup.16 (where t is 1 to 2),
--R.sup.15--S(O).sub.tR.sup.16 (where t is 0 to 2), and
--R.sup.15--S(O).sub.tN(R.sup.14).sub.2 (where t is 1 to 2) where
each R.sup.14 is independently hydrogen, alkyl, alkenyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R.sup.15 is
independently a direct bond or a straight or branched alkylene or
alkenylene chain; and each R.sup.16 is alkyl, alkenyl, haloalkyl,
cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
heterocyclylalkyl, heteroaryl or heteroarylalkyl, and where each of
the above substituents is unsubstituted.
[0111] "C.sub.1-C.sub.12heteroaryl" refers to a heteroaryl radical
as defined above having one to twelve carbon atoms. The
C.sub.1-C.sub.12heteroaryl group may be optionally substituted as
defined above for a heteroaryl group.
[0112] "C.sub.5-C.sub.12heteroaryl" refers to a heteroaryl radical
as defined above having five to twelve carbon atoms. The
C.sub.5-C.sub.12heteroaryl group may be optionally substituted as
defined above for a heteroaryl group.
[0113] "Heteroarylalkyl" refers to a radical of the formula
--R.sub.aR.sub.f where R.sub.a is an alkyl radical as defined above
and R.sub.f is a heteroaryl radical as defined above. The
heteroaryl part of the heteroarylalkyl radical may be optionally
substituted as defined above for a heteroaryl group. The alkyl part
of the heteroarylalkyl radical may be optionally substituted as
defined above for an alkyl group.
[0114] "C.sub.3-C.sub.12heteroarylalkyl" refers to a
heteroarylalkyl radical as defined above having three to twelve
carbon atoms. The C.sub.3-C.sub.12heteroarylalkyl group may be
optionally substituted as defined above for a heteroarylalkyl
group.
[0115] "Heteroarylcycloalkyl" refers to a radical of the formula
--R.sub.dR.sub.f where R.sub.d is a cycloalkyl radical as defined
above and R.sub.f is a heteroaryl radical as defined above. The
cycloalkyl part of the heteroarylcycloalkyl radical may be
optionally substituted as defined above for a cycloalkyl group. The
heteroaryl part of the heteroarylcycloalkyl radical may be
optionally substituted as defined above for a heteroaryl group.
[0116] "Heteroarylalkenyl" refers to a radical of the formula
--R.sub.bR.sub.f where R.sub.b is an alkenyl radical as defined
above and R.sub.f is a heteroaryl radical as defined above. The
heteroaryl part of the heteroarylalkenyl radical may be optionally
substituted as defined above for a heteroaryl group. The alkenyl
part of the heteroarylalkenyl radical may be optionally substituted
as defined above for an alkenyl group.
[0117] "Hydroxyalkyl" refers to a radical of the formula
--R.sub.a--OH where R.sub.a is an alkyl radical as defined above.
The hydroxy group may be attached to the alkyl radical on any
carbon within the alkyl radical. The alkyl part of the hydroxyalkyl
group may be optionally substituted as defined above for an alkyl
group.
[0118] "C.sub.2-C.sub.12hydroxyalkyl" refers to a hydroxyalkyl
radical as defined above containing two to twelve carbon atoms. The
alkyl part of the C.sub.2-C.sub.12hydroxyalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0119] "C.sub.3-C.sub.12hydroxyalkyl" refers to a hydroxyalkyl
radical as defined above containing three to twelve carbon atoms.
The alkyl part of the C.sub.3-C.sub.12hydroxyalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0120] "C.sub.7-C.sub.12hydroxyalkyl" refers to a hydroxyalkyl
radical as defined above containing seven to twelve carbon atoms.
The alkyl part of the C.sub.7-C.sub.12hydroxyalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0121] "Hydroxyalkenyl" refers to a radical of the formula
--R.sub.c--OH where R.sub.c is an alkenyl radical as defined above.
The hydroxy group may be attached to the alkenyl radical on any
carbon within the alkenyl radical. The alkenyl part of the
hydroxyalkenyl group may be optionally substituted as defined above
for an alkenyl group.
[0122] "C.sub.2-C.sub.12hydroxyalkenyl" refers to a hydroxyalkenyl
radical as defined above containing two to twelve carbon atoms. The
alkenyl part of the C.sub.2-C.sub.12hydroxyalkenyl radical may be
optionally substituted as defined above for an alkenyl group.
[0123] "C.sub.3-C.sub.12hydroxyalkenyl" refers to a hydroxyalkenyl
radical as defined above containing three to twelve carbon atoms.
The alkenyl part of the C.sub.3-C.sub.12hydroxyalkenyl radical may
be optionally substituted as defined above for an alkenyl
group.
[0124] "Hydroxyl-C.sub.1-C.sub.6-alkyl" refers to a radical of the
formula --R.sub.h--OH where R.sub.h is an unbranched alkyl radical
having one to six carbons and the hydroxy radical is attached to
the terminal carbon.
[0125] "Trihaloalkyl" refers to an alkyl radical, as defined above,
that is substituted by three halo radicals, as defined above, e.g.,
trifluoromethyl. The alkyl part of the trihaloalkyl radical may be
optionally substituted as defined above for an alkyl group.
[0126] "C.sub.1-C.sub.6-trihaloalkyl" refers to a trihaloalkyl
radical as defined above having one to six carbon atoms. The
C.sub.1-C.sub.6-trihaloalkyl may be optionally substituted as
defined above for a trihaloalkyl group.
[0127] "Trihaloalkoxy" refers to a radical of the formula
--OR.sub.g where R.sub.g is a trihaloalkyl group as defined above.
The trihaloalkyl part of the trihaloalkoxy group may be optionally
substituted as defined above for a trihaloalkyl group.
[0128] "C.sub.1-C.sub.6-trihaloalkoxy" refers to a trihaloalkoxy
radical as defined above having one to six carbon atoms. The
C.sub.1-C.sub.6trihaloalkoxy group may be optionally substituted as
defined above for a trihaloalkoxy group.
[0129] "A multi-ring structure" refers to a multicyclic ring system
comprised of two to four rings wherein the rings are independently
selected from cycloalkyl, aryl, heterocyclyl or heteroaryl as
defined above. Each cycloalkyl may be optionally substituted as
defined above for a cycloalkyl group. Each aryl may be optionally
substituted as defined above for an aryl group. Each heterocyclyl
may be optionally substituted as defined above for a heterocyclyl
group. Each heteroaryl may be optionally substituted as defined
above for a heteroaryl group. The rings may be attached to other
through direct bonds or some or all of the rings may be fused to
each other. Examples include, but are not limited to a cycloalkyl
radical substituted by aryl group; a cycloalkyl group substituted
by an aryl group, which, in turn, is substituted by another aryl
group; and so forth.
[0130] "Prodrugs" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound of the invention. Thus, the term
"prodrug" refers to a metabolic precursor of a compound of the
invention that is pharmaceutically acceptable. A prodrug may be
inactive when administered to a subject in need thereof, but is
converted in vivo to an active compound of the invention. Prodrugs
are typically rapidly transformed in vivo to yield the parent
compound of the invention, for example, by hydrolysis in blood. The
prodrug compound often offers advantages of solubility, tissue
compatibility or delayed release in a mammalian organism (see,
Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,
Amsterdam).
[0131] A discussion of prodrugs is provided in Higuchi, T., et al.,
"Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series,
Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward
B. Roche, American Pharmaceutical Association and Pergamon Press,
1987, both of which are incorporated in full by reference
herein.
[0132] The term "prodrug" is also meant to include any covalently
bonded carriers which release the active compound of the invention
in vivo when such prodrug is administered to a mammalian subject.
Prodrugs of a compound of the invention may be prepared by
modifying functional groups present in the compound of the
invention in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to the parent compound of the
invention. Prodrugs include compounds of the invention wherein a
hydroxy, amino or mercapto group is bonded to any group that, when
the prodrug of the compound of the invention is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amine functional groups in the compounds of the
invention and the like.
[0133] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0134] "Mammal" includes humans and domestic animals, such as cats,
dogs, swine, cattle, sheep, goats, horses, rabbits, and the
like.
[0135] "Optional" or "optionally" means that the subsequently
described event of circumstances may or may not occur, and that the
description includes instances where said event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
[0136] "Pharmaceutically acceptable carrier, diluent or excipient"
includes without limitation any adjuvant, carrier, excipient,
glidant, sweetening agent, diluent, preservative, dye/colorant,
flavor enhancer, surfactant, wetting agent, dispersing agent,
suspending agent, stabilizer, isotonic agent, solvent, or
emulsifier which has been approved by the United States Food and
Drug Administration as being acceptable for use in humans or
domestic animals.
[0137] "Pharmaceutically acceptable salt" includes both acid and
base addition salts.
[0138] "Pharmaceutically acceptable acid addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free bases, which are not biologically or
otherwise undesirable, and which are formed with inorganic acids
such as, but not limited to, hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, and
organic acids such as, but not limited to, acetic acid,
2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid,
aspartic acid, benzenesulfonic acid, benzoic acid,
4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid,
capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic
acid, citric acid, cyclamic acid, dodecylsulfuric acid,
ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric
acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic
acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid,
glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric
acid, lactic acid, lactobionic acid, lauric acid, maleic acid,
malic acid, malonic acid, mandelic acid, methanesulfonic acid,
mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic
acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid,
orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic
acid, pyroglutamic acid, pyruvic acid, salicylic acid,
4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid,
tartaric acid, thiocyanic acid, p-toluenesulfonic acid,
trifluoroacetic acid, undecylenic acid, and the like.
[0139] "Pharmaceutically acceptable base addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free acids, which are not biologically or
otherwise undesirable. These salts are prepared from addition of an
inorganic base or an organic base to the free acid. Salts derived
from inorganic bases include, but are not limited to, the sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese, aluminum salts and the like. Preferred inorganic
salts are the ammonium, sodium, potassium, calcium, and magnesium
salts. Salts derived from organic bases include, but are not
limited to, salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
ammonia, isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, diethanolamine, ethanolamine,
deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,
hydrabamine, choline, betaine, benethamine, benzathine,
ethylenediamine, glucosamine, methylglucamine, theobromine,
triethanolamine, tromethamine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins and the like. Particularly
preferred organic bases are isopropylamine, diethylamine,
ethanolamine, trimethylamine, dicyclohexylamine, choline and
caffeine.
[0140] Often crystallizations produce a solvate of the compound of
the invention. As used herein, the term "solvate" refers to an
aggregate that comprises one or more molecules of a compound of the
invention with one or more molecules of solvent. The solvent may be
water, in which case the solvate may be a hydrate. Alternatively,
the solvent may be an organic solvent. Thus, the compounds of the
present invention may exist as a hydrate, including a monohydrate,
dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and
the like, as well as the corresponding solvated forms. The compound
of the invention may be true solvates, while in other cases, the
compound of the invention may merely retain adventitious water or
be a mixture of water plus some adventitious solvent.
[0141] A "pharmaceutical composition" refers to a formulation of a
compound of the invention and a medium generally accepted in the
art for the delivery of the biologically active compound to
mammals, e.g., humans. Such a medium includes all pharmaceutically
acceptable carriers, diluents or excipients therefor.
[0142] "Therapeutically effective amount" refers to that amount of
a compound of the invention which, when administered to a mammal,
preferably a human, is sufficient to effect treatment, as defined
below, of an SCD-mediated disease or condition in the mammal,
preferably a human. The amount of a compound of the invention which
constitutes a "therapeutically effective amount" will vary
depending on the compound, the condition and its severity, and the
age of the mammal to be treated, but can be determined routinely by
one of ordinary skill in the art having regard to his own knowledge
and to this disclosure.
[0143] "Treating" or "treatment" as used herein covers the
treatment of the disease or condition of interest in a mammal,
preferably a human, having the disease or disorder of interest, and
includes:
[0144] (i) preventing the disease or condition from occurring in a
mammal, in particular, when such mammal is predisposed to the
condition but has not yet been diagnosed as having it;
[0145] (ii) inhibiting the disease or condition, i.e., arresting
its development; or
[0146] (iii) relieving the disease or condition, i.e., causing
regression of the disease or condition.
[0147] As used herein, the terms "disease" and "condition" may be
used interchangeably or may be different in that the particular
malady or condition may not have a known causative agent (so that
etiology has not yet been worked out) and it is therefore not yet
recognized as a disease but only as an undesirable condition or
syndrome, wherein a more or less specific set of symptoms have been
identified by clinicians.
[0148] The compounds of the invention, or their pharmaceutically
acceptable salts may contain one or more asymmetric centers and may
thus give rise to enantiomers, diastereomers, and other
stereoisomeric forms that may be defined, in terms of absolute
stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino
acids. The present invention is meant to include all such possible
isomers, as well as their racemic and optically pure forms.
Optically active (+) and (-), (R)- and (S)-, or (D)- and
(L)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques, such as HPLC
using a chiral column. When the compounds described herein contain
olefinic double bonds or other centers of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are also intended to be included.
[0149] A "stereoisomer" refers to a compound made up of the same
atoms bonded by the same bonds but having different
three-dimensional structures, which are not interchangeable. The
present invention contemplates various stereoisomers and mixtures
thereof and includes "enantiomers", which refers to two
stereoisomers whose molecules are nonsuperimposeable mirror images
of one another.
[0150] A "tautomer" refers to a proton shift from one atom of a
molecule to another atom of the same molecule. The present
invention includes tautomers of any said compounds.
[0151] The chemical naming protocol and structure diagrams used
herein employ and rely the chemical naming features as utilized by
Chemdraw version 7.0.1 (available from Cambridgesoft Corp.,
Cambridge, Mass.). For complex chemical names employed herein, a
substituent group is named before the group to which it attaches.
For example, cyclopropylethyl comprises an ethyl backbone with
cyclopropyl substituent. In chemical structure diagrams, all bonds
are identified, except for some carbon atoms which are assumed to
be bonded to sufficient hydrogen atoms to complete the valency.
[0152] For example, a compound of formula (I) wherein x and y are
each 1; J and K are both N; L is N; M is --N.dbd.; W is a direct
bond; V is --C(O)--; R.sup.2 is n-pentyl; R.sup.3 is
2-trifluoromethylphenyl; and R.sup.5, R.sup.5a, R.sup.6, R.sup.6a,
R.sup.7, R.sup.7a, R.sup.8 and R.sup.8aa are each hydrogen, i.e., a
compound of the following formula:
##STR00004##
is named herein as
[4-(2-Pentylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl](2-trifluoromethy-
lphenyl)methanone.
[0153] Certain radical groups of the compounds of the invention are
depicted herein as linkages between two parts of the compounds of
the invention. For example, in the following formula (I):
##STR00005##
W is described, for example, as being --N(R.sup.1)C(O)--,
--C(O)N(R.sup.1)--, or --N(R.sup.1)C(O)N(R.sup.1)--; and V is
described, for example, as being --C(O)-- or --C(S)--. This
description is meant to describe a W group attached to the R.sup.2
group as follows: R.sup.2--N(R.sup.1)C(O)--,
R.sup.2--C(O)N(R.sup.1)--, or R.sup.2--N(R.sup.1)C(O)N(R.sup.1)--;
and a V group attached to the R.sup.3 group as follows:
--C(O)--R.sup.3 or --C(S)--R.sup.3. In other words, the
descriptions of the W and V linkage groups are meant to be read
from left to right in view of formula (I) as depicted above.
EMBODIMENTS OF THE INVENTION
[0154] Of the compounds of formula (I) set forth above in the
Summary of the Invention, one embodiment includes those compounds
of formula (I) wherein J and K are both N, i.e., a compound having
the following formula (Ia):
##STR00006##
[0155] Of this group of compounds, a subgroup of compounds includes
those compounds wherein x and y are each 1; L is N; M is --N.dbd.;
W is a direct bond, --N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--,
--OC(O)N(R.sup.1)--, --N(R.sup.1)C(O)N(R.sup.1)--, --O--,
--N(R.sup.1)--, --S(O).sub.t-- (where t is 0, 1 or 2),
--N(R.sup.1)S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O--, or --C(R.sup.1).sub.2--; V is --N(R.sup.1)--,
--N(R.sup.1)C(O)--, --C(O)--, --C(O)O--, --C(S)--,
--C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or --C(R.sup.10)H--;
each R.sup.1 is independently selected from the group consisting of
hydrogen, C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12hydroxyalkyl,
C.sub.4-C.sub.12cycloalkylalkyl and C.sub.7-C.sub.19aralkyl;
R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and C.sub.3-C.sub.12heteroarylalkyl;
R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl;
R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8
and R.sup.8a are each independently selected from hydrogen or
C.sub.1-C.sub.3alkyl; and R.sup.10 is hydrogen or
C.sub.1-C.sub.3alkyl.
[0156] Of this subgroup of compounds, a set of compounds includes
those compounds where W is --N(R.sup.1)C(O)-- and V is
--C(O)--.
[0157] Specific embodiments of this set of compounds include, but
are not limited to, the following compounds: [0158]
6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid (3-methylbutyl)amide; [0159]
6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)-piperazin-1-yl]-imidazo[1,2-b]py-
ridazine-2-carboxylic acid pentylamide; [0160]
6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)-piperazin-1-yl]-imidazo[1,2-b]py-
ridazine-2-carboxylic acid [2-(4-fluoro-phenyl)ethyl]amide; [0161]
6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)-piperazin-1-yl]-imidazo[1,2-b]py-
ridazine-2-carboxylic acid 4-fluorobenzylamide; [0162]
6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)-piperazin-1-yl]-imidazo[1,2-b]py-
ridazine-2-carboxylic acid (3-cyclopropylpropyl)amide; [0163]
6-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]pyridazine-
-2-carboxylic acid pentylamide; [0164]
6-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]pyridazine-
-2-carboxylic acid butylamide; [0165]
6-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]pyridazine-
-2-carboxylic acid (5-chloro-pyridin-2-yl)-amide; [0166]
6-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]pyridazine-
-2-carboxylic acid 4-fluoro-benzylamide; [0167]
6-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]pyridazine-
-2-carboxylic acid (4-fluoro-phenyl)-amide; [0168]
6-[4-(5-Fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]p-
yridazine-2-carboxylic acid hexylamide; and [0169]
6-[4-(5-Fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-imidazo[1,2-b]p-
yridazine-2-carboxylic acid butylamide.
[0170] Of the subgroup of compounds above, another set of compounds
includes those compounds where W is a direct bond and V is
--C(O--.
[0171] Specific embodiments of this set of compounds include, but
are not limited to, the following compounds: [0172]
[4-(2-Ethylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl](2-trifluoromethyl-
-phenyl)methanone; [0173]
[4-(2-Pentylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl](2-trifluoromethy-
l-phenyl)methanone; and [0174]
[4-(2-Butylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]-(2-trifluoromethy-
l-phenyl)methanone.
[0175] In another embodiment of the invention, a group of compounds
of formula (I) is directed to compounds where K is C(R.sup.11) and
V is --N(R.sup.1)--, --N(R.sup.1)C(O)--, --C(O)--, --C(O)O--,
--C(S)--, --C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or
--C(R.sup.10)H--.
[0176] In yet another embodiment of the invention, a group of
compounds of formula (I) is directed to compounds where K is N and
V is --C(O)--, --C(O)O--, --C(S)--, --C(O)N(R.sup.1)--,
--S(O).sub.p-- (where p is 1 or 2), --S(O).sub.pN(R.sup.1)-- (where
p is 1 or 2), or --C(R.sup.10)H--.
[0177] In yet another embodiment of the invention, a group of
compounds of formula (II) as set forth above in the Summary of the
Invention is directed to compounds where A and E are each
independently NH depending on the resonance requirement of the
ring.
[0178] In yet another embodiment of the invention, a group of
compounds of formula (II) as set forth above in the Summary of the
Invention is directed to the compounds of the following formula
(IIa):
##STR00007##
[0179] wherein x and y are each independently 1, 2 or 3;
[0180] W is a direct bond, --N(R.sup.1)C(O)--, --C(O)N(R.sup.1)--,
--OC(O)N(R.sup.1)--, --N(R.sup.1)C(O)N(R.sup.1)--, --O--,
--N(R.sup.1)--, --S(O).sub.t-- (where t is 0, 1 or 2),
--N(R.sup.1)S(O).sub.p-- (where p is 1 or 2),
--S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), --C(O)--,
--OS(O).sub.2N(R.sup.1)--, --OC(O)--, --C(O)O--,
--N(R.sup.1)C(O)O-- or --C(R.sup.1).sub.2--;
[0181] V is --N(R.sup.1)--, --N(R.sup.1)C(O)--, --C(O)--,
--C(O)O--, --C(S)--, --C(O)N(R.sup.1)--, --S(O).sub.p-- (where p is
1 or 2), --S(O).sub.pN(R.sup.1)-- (where p is 1 or 2), or
--C(R.sup.10)H--;
[0182] each R.sup.1 is independently selected from the group
consisting of hydrogen, C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.4-C.sub.12cycloalkylalkyl and
C.sub.7-C.sub.19aralkyl;
[0183] R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and
C.sub.3-C.sub.12heteroarylalkyl;
[0184] or R.sup.2 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0185] R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl;
[0186] or R.sup.3 is a multi-ring structure having 2 to 4 rings
wherein the rings are independently selected from the group
consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and
where some or all of the rings may be fused to each other;
[0187] R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each independently selected from hydrogen
or C.sub.1-C.sub.3alkyl;
[0188] or R.sup.5 and R.sup.5a together, R.sup.6 and R.sup.6a
together, or R.sup.7 and R.sup.7a together, or R.sup.8 and R.sup.8a
together are an oxo group, provided that when V is --C(O)--,
R.sup.6 and R.sup.6a, together or R.sup.8 and R.sup.8a together do
not form an oxo group, while the remaining R.sup.5, R.sup.5a,
R.sup.6, R.sup.6a, R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a are each
independently selected from hydrogen or C.sub.1-C.sub.3alkyl;
[0189] or one of R.sup.5, R.sup.5a, R.sup.6 and R.sup.6a together
with one of R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a forms a direct
bond or an alkylene bridge, while the remaining R.sup.5, R.sup.5a,
R.sup.6a, R.sup.7, R.sup.7a, R.sup.8, and R.sup.8a are each
independently selected from hydrogen or C.sub.1-C.sub.3alkyl;
and
[0190] R.sup.10 is hydrogen or C.sub.1-C.sub.3alkyl.
[0191] Of this group of compounds of formula (IIa), one subgroup is
directed to compounds wherein:
[0192] x and y are each 1;
[0193] W is a direct bond, --N(R.sup.1)C(O)--, or
--C(O)N(R.sup.1)--;
[0194] V is --C(O)--;
[0195] each R.sup.1 is independently selected from the group
consisting of hydrogen, C.sub.1-C.sub.12alkyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.4-C.sub.12cycloalkylalkyl and
C.sub.7-C.sub.19aralkyl;
[0196] R.sup.2 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl, and
C.sub.3-C.sub.12heteroarylalkyl;
[0197] R.sup.3 is selected from the group consisting of
C.sub.1-C.sub.12alkyl, C.sub.2-C.sub.12alkenyl,
C.sub.2-C.sub.12hydroxyalkyl, C.sub.2-C.sub.12hydroxyalkenyl,
C.sub.2-C.sub.12alkoxyalkyl, C.sub.3-C.sub.12cycloalkyl,
C.sub.4-C.sub.12cycloalkylalkyl, aryl, C.sub.7-C.sub.19aralkyl,
C.sub.3-C.sub.12heterocyclyl, C.sub.3-C.sub.12heterocyclylalkyl,
C.sub.1-C.sub.12heteroaryl and C.sub.3-C.sub.12heteroarylalkyl;
and
[0198] R.sup.5, R.sup.5a, R.sup.6, R.sup.6a, R.sup.7, R.sup.7a,
R.sup.8 and R.sup.8a are each hydrogen.
[0199] Specific embodiments of this subgroup of compounds include,
but are not limited to, the following compounds: [0200]
[4-(2-Propyl-1H-benzoimidazol-5-yl)piperazin-1-yl](2-trifluoromethyl-phen-
yl)methanone; and [0201]
[4-(2-Pentyl-1H-benzoimidazol-5-yl)piperazin-1-yl](2-trifluoromethyl-phen-
yl)methanone.
[0202] Preparation and use of the specific embodiments of the
compounds of formula (I) and formula (II) are disclosed herein in
the Reaction Schemes, Preparations and Examples set forth
below.
[0203] In one embodiment, the methods of the invention are directed
towards the treatment and/or prevention of diseases mediated by
stearoyl-CoA desaturase (SCD), especially human SCD (hSCD),
preferably diseases related to dyslipidemia and disorders of lipid
metabolism, and especially a disease related to elevated plasma
lipid levels, cardiovascular disease, diabetes, obesity, metabolic
syndrome and the like by administering an effective amount of a
compound of the invention.
[0204] The present invention also relates to pharmaceutical
composition containing the compounds of the invention. In one
embodiment, the invention relates to a composition comprising
compounds of the invention in a pharmaceutically acceptable carrier
and in an amount effective to modulate triglyceride level or to
treat diseases related to dyslipidemia and disorders of lipid
metabolism, when administered to an animal, preferably a mammal,
most preferably a human patient. In an embodiment of such
composition, the patient has an elevated lipid level, such as
elevated triglycerides or cholesterol, before administration of
said compound of the invention and the compound of the invention is
present in an amount effective to reduce said lipid level.
Utility and Testing of the Compounds of the Invention
[0205] The present invention relates to compounds, pharmaceutical
compositions and methods of using the compounds and pharmaceutical
compositions for the treatment and/or prevention of diseases
mediated by stearoyl-CoA desaturase (SCD), especially human SCD
(hSCD), preferably diseases related to dyslipidemia and disorders
of lipid metabolism, and especially a disease related to elevated
plasma lipid levels, especially cardiovascular disease, diabetes,
obesity, metabolic syndrome and the like, by administering to a
patient in need of such treatment an effective amount of an
SCD-modulating, especially inhibiting, agent.
[0206] In general, the present invention provides a method for
treating a patient for, or protecting a patient from developing, a
disease related to dyslipidemia and/or a disorder of lipid
metabolism, wherein lipid levels in an animal, especially a human
being, are outside the normal range (i.e., abnormal lipid level,
such as elevated plasma lipid levels), especially levels higher
than normal, preferably where said lipid is a fatty acid, such as a
free or complexed fatty acid, triglycerides, phospholipids, or
cholesterol, such as where LDL-cholesterol levels are elevated or
HDL-cholesterol levels are reduced, or any combination of these,
where said lipid-related condition or disease is an SCD-mediated
disease or condition, comprising administering to an animal, such
as a mammal, especially a human patient, a therapeutically
effective amount of a compound of the invention or a pharmaceutical
composition comprising a compound of the invention wherein the
compound modulates the activity of SCD, preferably human SCD1.
[0207] The compounds of the invention modulate, preferably inhibit,
the activity of human SCD enzymes, especially human SCD1.
[0208] The general value of the compounds of the invention in
modulating, especially inhibiting, the activity of SCD can be
determined using the assay described below in Example 4.
Alternatively, the general value of the compounds in treating
disorders and diseases may be established in industry standard
animal models for demonstrating the efficacy of compounds in
treating obesity, diabetes or elevated triglyceride or cholesterol
levels or for improving glucose tolerance. Such models include
Zucker obese fa/fa rats (available from Harlan Sprague Dawley, Inc.
(Indianapolis, Ind.)), or the Zucker diabetic fatty rat
(ZDF/GmiCrl-fa/fa) (available from Charles River Laboratories
(Montreal, Quebec)).
[0209] The compounds of the instant invention are inhibitors of
delta-9 desaturases and are useful for treating diseases and
disorders in humans and other organisms, including all those human
diseases and disorders which are the result of aberrant delta-9
desaturase biological activity or which may be ameliorated by
modulation of delta-9 desaturase biological activity.
[0210] As defined herein, an SCD-mediated disease or condition
includes but is not limited to a disease or condition which is, or
is related to, cardiovascular disease, dyslipidemias (including but
not limited to disorders of serum levels of triglycerides,
hypertriglyceridemia, VLDL, HDL, LDL, fatty acid Desaturation Index
(e.g. the ratio of 18:1/18:0 fatty acids, or other fatty acids, as
defined elsewhere herein), cholesterol, and total cholesterol,
hypercholesterolemia, as well as cholesterol disorders (including
disorders characterized by defective reverse cholesterol
transport), familial combined hyperlipidemia, coronary artery
disease, atherosclerosis, heart disease, cerebrovascular disease
(including but not limited to stroke, ischemic stroke and transient
ischemic attack (TIA)), peripheral vascular disease, and ischemic
retinopathy. In a preferred embodiment, compounds of the invention
will, in a patient, increase HDL levels and/or decrease
triglyceride levels and/or decrease LDL or non-HDL-cholesterol
levels.
[0211] An SCD-mediated disease or condition also includes metabolic
syndrome (including but not limited to dyslipidemia, obesity and
insulin resistance, hypertension, microalbuminemia, hyperuricaemia,
and hypercoagulability), Syndrome X, diabetes, insulin resistance,
decreased glucose tolerance, non-insulin-dependent diabetes
mellitus, Type II diabetes, Type I diabetes, diabetic
complications, body weight disorders (including but not limited to
obesity, overweight, cachexia and anorexia), weight loss, body mass
index and leptin related diseases. In a preferred embodiment,
compounds of the invention will be used to treat diabetes mellitus
and obesity.
[0212] As used herein, the term "metabolic syndrome" is a
recognized clinical term used to describe a condition comprising
combinations of Type II diabetes, impaired glucose tolerance,
insulin resistance, hypertension, obesity, increased abdominal
girth, hypertriglyceridemia, low HDL, hyperuricaemia,
hypercoagulability and/or microalbuminemia.
[0213] An SCD-mediated disease or condition also includes fatty
liver, hepatic steatosis, hepatitis, non-alcoholic hepatitis,
non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute
fatty liver, fatty liver of pregnancy, drug-induced hepatitis,
erythrohepatic protoporphyria, iron overload disorders, hereditary
hemochromatosis, hepatic fibrosis, hepatic cirrhosis, hepatoma and
conditions related thereto.
[0214] An SCD-mediated disease or condition also includes but is
not limited to a disease or condition which is, or is related to
primary hypertriglyceridemia, or hypertriglyceridemia secondary to
another disorder or disease, such as hyperlipoproteinemias,
familial histiocytic reticulosis, lipoprotein lipase deficiency,
apolipoprotein deficiency (such as ApoCII deficiency or ApoE
deficiency), and the like, or hypertriglyceridemia of unknown or
unspecified etiology.
[0215] An SCD-mediated disease or condition also includes a
disorder of polyunsaturated fatty acid (PUFA) disorder, or a skin
disorder, including but not limited to eczema, acne, psoriasis,
keloid scar formation or prevention, diseases related to production
or secretions from mucous membranes, such as monounsaturated fatty
acids, wax esters, and the like.
[0216] An SCD-mediated disease or condition also includes
inflammation, sinusitis, asthma, pancreatitis, osteoarthritis,
rheumatoid arthritis, cystic fibrosis, and premenstrual
syndrome.
[0217] An SCD-mediated disease or condition also includes but is
not limited to a disease or condition which is, or is related to
cancer, neoplasia, malignancy, metastases, tumours (benign or
malignant), carcinogenesis, hepatomas and the like.
[0218] An SCD-mediated disease or condition also includes a
condition where increasing lean body mass or lean muscle mass is
desired, such as is desirable in enhancing performance through
muscle building. Myopathies and lipid myopathies such as carnitine
palmitoyltransferase deficiency (CPT I or CPT II) are also included
herein. Such treatments are useful in humans and in animal
husbandry, including for administration to bovine, porcine or avian
domestic animals or any other animal to reduce triglyceride
production and/or provide leaner meat products and/or healthier
animals.
[0219] An SCD-mediated disease or condition also includes a disease
or condition which is, or is related to, neurological diseases,
psychiatric disorders, multiple sclerosis, eye diseases, and immune
disorders.
[0220] An SCD-mediated disease or condition also includes a disease
or condition which is, or is related to, viral diseases or
infections including but not limited to all positive strand RNA
viruses, coronaviruses, SARS virus, SARS-associated coronavirus,
Togaviruses, Picornaviruses, Coxsackievirus, Yellow Fever virus,
Flaviviridae, ALPHAVIRUS (TOGAVIRIDAE) including Rubella virus,
Eastern equine encephalitis virus, Western equine encephalitis
virus, Venezuelan equine encephalitis virus, Sindbis virus, Semliki
forest virus, Chikungunya virus, O'nyong'nyong virus, Ross river
virus, Mayaro virus, Alphaviruses; ASTROVIRIDAE including
Astrovirus, Human Astroviruses; CALICIVIRIDAE including Vesicular
exanthema of swine virus, Norwalk virus, Calicivirus, Bovine
calicivirus, Pig calcivirus, Hepatitis E; CORONAVIRIDAE including
Coronavirus, SARS virus, Avian infectious bronchitis virus, Bovine
coronavirus, Canine coronavirus, Feline infectious peritonitis
virus, Human coronavirus 299E, Human coronavirus OC43, Murine
hepatitis virus, Porcine epidemic diarrhea virus, Porcine
hemagglutinating encephalomyelitis virus, Porcine transmissible
gastroenteritis virus, Rat coronavirus, Turkey coronavirus, Rabbit
coronavirus, Berne virus, Breda virus; FLAVIVIRIDAE including
Hepatitis C virus, West Nile virus, Yellow Fever virus, St. Louis
encephalitis virus, Dengue Group, Hepatitis G virus, Japanese B
encephalitis virus, Murray Valley encephalitis virus, Central
European tick-borne encephalitis virus, Far Eastern tick-borne
encephalitis virus, Kyasanur forest virus, Louping ill virus,
Powassan virus, Omsk hemorrhagic fever virus, Kumilinge virus,
Absetarov anzalova hypr virus, llheus virus, Rocio encephalitis
virus, Langat virus, Pestivirus, Bovine viral diarrhea, Hog cholera
virus, Rio Bravo Group, Tyuleniy Group, Ntaya Group, Uganda S
Group, Modoc Group; PICORNAVIRIDAE including Coxsackie A virus,
Rhinovirus, Hepatitis A virus, Encephalomyocarditis virus,
Mengovirus, ME virus, Human poliovirus 1, Coxsackie B; POTYVIRIDAE
including Potyvirus, Rymovirus, Bymovirus. Additionally it can be a
disease or infection caused by or linked to Hepatitis viruses,
Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus
(HIV) and the like. Treatable viral infections include those where
the virus employs an RNA intermediate as part of the replicative
cycle (hepatitis or HIV); additionally it can be a disease or
infection caused by or linked to RNA negative strand viruses such
as influenza and parainfluenza viruses.
[0221] The compounds identified in the instant specification
inhibit the desaturation of various fatty acids (such as the C9-C10
desaturation of stearoyl-CoA) which is accomplished by delta-9
desaturases, such as stearoyl-CoA desaturase 1 (SCD1). As such
these compounds inhibit the formation of various fatty acids and
downstream metabolites thereof. This may lead to an accumulation of
stearoyl-CoA or palmitoyl-CoA and other upstream precursors of
various fatty acids; which may possibly result in a negative
feedback loop causing an overall change in fatty acid metabolism.
Any of these consequences may ultimately be responsible for the
overall therapeutic benefit provided by these compounds.
[0222] Typically, a successful SCD inhibitory therapeutic agent
will meet some or all of the following criteria. Oral availability
should be at or above 20%. Animal model efficacy is less than about
2 mg/Kg, 1 mg/Kg, or 0.5 mg/Kg and the target human dose is between
50 and 250 mg/70 Kg, although doses outside of this range may be
acceptable. ("mg/Kg" means milligrams of compound per kilogram of
body mass of the subject to whom it is being administered). The
therapeutic index (or ratio of toxic dose to therapeutic dose)
should be greater than 100. The potency (as expressed by IC.sub.50
value) should be less than 10 .mu.M, preferably below 1 .mu.M and
most preferably below 50 nM. The IC.sub.50 ("Inhibitory
Concentration--50%") is a measure of the amount of compound
required to achieve 50% inhibition of SCD activity, over a specific
time period, in an SCD biological activity assay. Any process for
measuring the activity of SCD enzymes, preferably mouse or human
SCD enzymes, may be utilized to assay the activity of the compounds
useful in the methods of the invention in inhibiting said SCD
activity. Compounds of the invention demonstrate an IC.sub.50 in a
15 minute microsomal assay of preferably less than 10 .mu.M, less
than 5 .mu.M, less than 2.5 .mu.M, less than 1 .mu.M, less than 750
nM, less than 500 nM, less than 250 nM, less than 100 nM, less than
50 nM, and most preferably less than 20 nM. The compound of the
invention may show reversible inhibition (i.e., competitive
inhibition) and preferably does not inhibit other iron binding
proteins. The required dosage should preferably be no more than
about once or twice a day or at meal times.
[0223] The identification of compounds of the invention as SCD
inhibitors was readily accomplished using the SCD enzyme and
microsomal assay procedure described in Brownlie et al, supra. When
tested in this assay, compounds of the invention had less than 50%
remaining SCD activity at 10 .mu.M concentration of the test
compound, preferably less than 40% remaining SCD activity at 10
.mu.M concentration of the test compound, more preferably less than
30% remaining SCD activity at 10 .mu.M concentration of the test
compound, and even more preferably less than 20% remaining SCD
activity at 10 .mu.M concentration of the test compound, thereby
demonstrating that the compounds of the invention are potent
inhibitors of SCD activity.
[0224] These results provide the basis for analysis of the
structure-activity relationship (SAR) between test compounds and
SCD. Certain R groups tend to provide more potent inhibitory
compounds. SAR analysis is one of the tools those skilled in the
art may now employ to identify preferred embodiments of the
compounds of the invention for use as therapeutic agents.
[0225] Other methods of testing the compounds disclosed herein are
also readily available to those skilled in the art. Thus, in
addition, said contacting may be accomplished in vivo. In one such
embodiment, said contacting in step (a) is accomplished by
administering said chemical agent to an animal afflicted with a
triglyceride (TG)- or very low density lipoprotein (VLDL)-related
disorder and subsequently detecting a change in plasma triglyceride
level in said animal thereby identifying a therapeutic agent useful
in treating a triglyceride (TG)- or very low density lipoprotein
(VLDL)-related disorder. In such embodiment, the animal may be a
human, such as a human patient afflicted with such a disorder and
in need of treatment of said disorder.
[0226] In specific embodiments of such in vivo processes, said
change in SCD1 activity in said animal is a decrease in activity,
preferably wherein said SCD1 modulating agent does not
substantially inhibit the biological activity of a delta-5
desaturase, delta-6 desaturase or fatty acid synthetase.
[0227] The model systems useful for compound evaluation may
include, but are not limited to, the use of liver microsomes, such
as from mice that have been maintained on a high carbohydrate diet,
or from human donors, including persons suffering from obesity.
Immortalized cell lines, such as HepG2 (from human liver), MCF-7
(from human breast cancer) and 3T3-L1 (from mouse adipocytes) may
also be used. Primary cell lines, such as mouse primary
hepatocytes, are also useful in testing the compounds of the
invention. Where whole animals are used, mice used as a source of
primary hepatocyte cells may also be used wherein the mice have
been maintained on a high carbohydrate diet to increase SCD
activity in mirocrosomes and/or to elevate plasma triglyceride
levels (i.e., the 18:1/18:0 ratio); alternatively mice on a normal
diet or mice with normal triglyceride levels may be used. Mouse
models employing transgenic mice designed for hypertriglyceridemia
are also available as is the mouse phenome database. Rabbits and
hamsters are also useful as animal models, especially those
expressing CETP (cholesteryl ester transfer protein).
[0228] Another suitable method for determining the in vivo efficacy
of the compounds of the invention is to indirectly measure their
impact on inhibition of SCD enzyme by measuring a subject's
Desaturation Index after administration of the compound.
"Desaturation Index" as employed in this specification means the
ratio of the product over the substrate for the SCD enzyme as
measured from a given tissue sample. This may be calculated using
three different equations 18:1n-9/18:0 (oleic acid over stearic
acid); 16:1n-7/16:0 (palmitoleic acid over palmitic acid); and/or
16:1n-7+18:1n-7/16:0 (measuring all reaction products of 16:0
desaturation over 16:0 substrate). Desaturation Index is primarily
measured in liver or plasma triglycerides, but may also be measured
in other selected lipid fractions from a variety of tissues.
Desaturation Index, generally speaking, is a tool for plasma lipid
profiling.
[0229] A number of human diseases and disorders are the result of
aberrant SCD1 biological activity and may be ameliorated by
modulation of SCD1 biological activity using the therapeutic agents
of the invention.
[0230] Inhibition of SCD expression may also affect the fatty acid
composition of membrane phospholipids, as well as production or
levels of triglycerides and cholesterol esters. The fatty acid
composition of phospholipids ultimately determines membrane
fluidity, while the effects on the composition of triglycerides and
cholesterol esters can affect lipoprotein metabolism and
adiposity.
[0231] In carrying out the procedures of the present invention it
is of course to be understood that reference to particular buffers,
media, reagents, cells, culture conditions and the like are not
intended to be limiting, but are to be read so as to include all
related materials that one of ordinary skill in the art would
recognize as being of interest or value in the particular context
in which that discussion is presented. For example, it is often
possible to substitute one buffer system or culture medium for
another and still achieve similar, if not identical, results. Those
of skill in the art will have sufficient knowledge of such systems
and methodologies so as to be able, without undue experimentation,
to make such substitutions as will optimally serve their purposes
in using the methods and procedures disclosed herein.
Pharmaceutical Compositions of the Invention and Administration
[0232] The present invention also relates to pharmaceutical
composition containing the compounds of the invention disclosed
herein. In one embodiment, the present invention relates to a
composition comprising compounds of the invention in a
pharmaceutically acceptable carrier and in an amount effective to
modulate triglyceride level or to treat diseases related to
dyslipidemia and disorders of lipid metabolism, when administered
to an animal, preferably a mammal, most preferably a human patient.
In an embodiment of such composition, the patient has an elevated
lipid level, such as elevated triglycerides or cholesterol, before
administration of said compound of the invention and the compound
of the invention is present in an amount effective to reduce said
lipid level.
[0233] The pharmaceutical compositions useful herein also contain a
pharmaceutically acceptable carrier, including any suitable diluent
or excipient, which includes any pharmaceutical agent that does not
itself induce the production of antibodies harmful to the
individual receiving the composition, and which may be administered
without undue toxicity. Pharmaceutically acceptable carriers
include, but are not limited to, liquids, such as water, saline,
glycerol and ethanol, and the like. A thorough discussion of
pharmaceutically acceptable carriers, diluents, and other
excipients is presented in REMINGTON'S PHARMACEUTICAL SCIENCES
(Mack Pub. Co., N.J. current edition).
[0234] Those skilled in the art know how to determine suitable
doses of the compounds for use in treating the diseases and
disorders contemplated herein. Therapeutic doses are generally
identified through a dose ranging study in humans based on
preliminary evidence derived from animal studies. Doses must be
sufficient to result in a desired therapeutic benefit without
causing unwanted side-effects for the patient. The preferred dosage
range for an animal is 0.001 mg/Kg to 10,000 mg/Kg, including 0.5
mg/Kg, 1.0 mg/Kg and 2.0 mg/Kg, though doses outside this range may
be acceptable. The dosing schedule may be once or twice per day,
although more often or less often may be satisfactory.
[0235] Those skilled in the art are also familiar with determining
administration methods (oral, intravenous, inhalation,
sub-cutaneous, etc.), dosage forms, suitable pharmaceutical
excipients and other matters relevant to the delivery of the
compounds to a subject in need thereof.
[0236] In an alternative use of the invention, the compounds of the
invention can be used in in vitro or in vivo studies as exemplary
agents for comparative purposes to find other compounds also useful
in treatment of, or protection from, the various diseases disclosed
herein.
Preparation of the Compounds of the Invention
[0237] It is understood that in the following description,
combinations of substituents and/or variables of the depicted
formulae are permissible only if such contributions result in
stable compounds.
[0238] It will also be appreciated by those skilled in the art that
in the process described below the functional groups of
intermediate compounds may need to be protected by suitable
protecting groups. Such functional groups include hydroxy, amino,
mercapto and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl or diarylalkylsilyl (e.g.,
t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),
tetrahydropyranyl, benzyl, and the like. Suitable protecting groups
for amino, amidino and guanidino include t-butoxycarbonyl,
benzyloxycarbonyl, and the like. Suitable protecting groups for
mercapto include --C(O)--R'' (where R'' is alkyl, aryl or
arylalkyl), p-methoxybenzyl, trityl and the like. Suitable
protecting groups for carboxylic acid include alkyl, aryl or
arylalkyl esters.
[0239] Protecting groups may be added or removed in accordance with
standard techniques, which are well-known to those skilled in the
art and as described herein.
[0240] The use of protecting groups is described in detail in
Green, T. W. and P. G. M. Wutz, Protective Groups in Organic
Synthesis (1999), 3rd Ed., Wiley. The protecting group may also be
a polymer resin such as a Wang resin or a 2-chlorotrityl-chloride
resin.
[0241] It will also be appreciated by those skilled in the art,
although such protected derivatives of compounds of this invention
may not possess pharmacological activity as such, they may be
administered to a mammal and thereafter metabolized in the body to
form compounds of the invention which are pharmacologically active.
Such derivatives may therefore be described as "prodrugs". All
prodrugs of compounds of this invention are included within the
scope of the invention.
[0242] The following Reaction Schemes illustrate methods to make
compounds of this invention. It is understood that one of those
skilled in the art would be able to make these compounds by similar
methods or by methods known to one skilled in the art. In general,
starting components may be obtained from sources such as Sigma
Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific,
TCI, and Fluorochem USA, etc. or synthesized according to sources
known to those skilled in the art (see, e.g., Advanced Organic
Chemistry: Reactions, Mechanisms, and Structure, 5th edition
(Wiley, December 2000)) or prepared as described in this invention.
R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.5a, R.sup.6, R.sup.6a,
R.sup.7, R.sup.7a, R.sup.8 and R.sup.8a are defined in the
following Reaction Schemes as in the Specification unless
specifically defined otherwise. PG represents a protecting group
such as BOC, benzyl group and the like.
[0243] In general, the compounds of formula (I) of this invention
can be synthesized following the general procedure as described in
Reaction Scheme 1 where J and K are both N, L and M are both
--N.dbd.; V is --C(O)--, and W is --N(R.sup.1)C(O)--.
##STR00008##
[0244] The starting materials for the above reaction scheme are
commercially available or can be prepared according to methods
known to one skilled in the art or by methods disclosed herein. In
general, the compounds of the invention are prepared in the above
reaction scheme as follows:
[0245] The ester compound 101 reacts with piperazine 102 in the
presence of a base such as, but not limited to, potassium carbonate
in a refluxing solvent such as, but not limited to, toluene to form
compound 103. Reaction of 103 with an appropriate acyl chloride in
the presence of a base such as, but not limited to,
diisopropylethylamine in a solvent such as, but not limited to,
dichloromethane gives the amide product 104. Conversion of the
ester group in 104 to an amide 105 can be performed by reaction
with an appropriate amine in the presence of sodium cyanide.
Alternatively, the ester group in 104 can be hydrolyzed to its
corresponding acid using a base such as, but not limited to,
lithium hydroxide. Thus, amide 105 can be formed from the acid of
104 by reaction with an appropriate amine in the presence of a base
such as, but not limited to, diisopropylethylamine,
1-hydroxyl-1H-benzotriazole and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in a solvent such as,
but not limited to, dichloromethane, or, by reaction of the acyl
chloride derivative of the acid of 104 with an appropriate amine in
the presence of a base such as, but not limited to,
diisopropylethylamine in a solvent such as, but not limited to,
dichloromethane.
[0246] In general, the compounds of formula (I) of this invention
where L and M are both N, V is --C(O)--, and W is a direct bond can
be synthesized following the general procedure as described in
Reaction Scheme 2.
##STR00009##
[0247] A protected piperazine 106 can react with an appropriate
acyl chloride in the presence of a base such as, but not limited
to, diisopropylethylamine in a solvent such as, but not limited to,
dichloromethane to give the amide product 107. The protecting
group, generally being a t-butyloxycarbonyl group, in compound 107
can be removed to give the desired product 108 by using acidic
conditions as described in Green, T. W. and P. G. M. Wutz,
Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley. The
mixture of 108 and chloroaminopyridazine 109 can be heated together
to provide the coupled product 110. Reaction of 110 with an
appropriate bromomethyl ketone in the presence of a base such as,
but not limited to, sodium bicarbonate in a solvent such as, but
not limited to, ethanol provides the final product 111.
[0248] Although anyone skilled in the art is capable of preparing
the compounds of the invention according to the general techniques
disclosed above, more specific details on synthetic techniques for
compounds of the invention are provided elsewhere in this
specification for convenience. Again, all reagents and reaction
conditions employed in synthesis are known to those skilled in the
art and are available from ordinary commercial sources. In
particular, one skilled in the art would readily recognize that
compounds of formula (II) can be prepared in the same manner as set
forth herein for compounds of formula (I) utilizing known methods
and reagents without undue experimentation.
PREPARATION 1
SYNTHESIS OF 6-PIPERAZIN-1-YLIMIDAZO[1,2-B]PYRIDAZINE-2-CARBOXYLIC
ACID ETHYL ESTER
[0249] A mixture of 6-chloroimidazo[1,2-b]pyridazine-2-carboxylic
acid ethyl ester (1.000 g, 4.432 mmol), piperizine (0.458 g, 5.318
mmol) and potassium carbonate (0.620 g, 4.485 mmol) in 50 mL of
toluene was refluxed for 48 hours. The reaction mixture was
concentrated in vacuo, diluted with water and extracted with ethyl
acetate. The crude product,
6-piperazin-1-ylimidazo[1,2-b]pyridazine-2-carboxylic acid ethyl
ester, obtained upon removal of solvent was used for next step
reaction without further purification. Yield 1.016 g, 83%.
PREPARATION 2
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID ETHYL ESTER
[0250] To a solution of
6-piperazin-1-ylimidazo[1,2-b]pyridazine-2-carboxylic acid ethyl
ester (1.016 g, 3.69 mmol) and diisopropylethylamine (1.29 mL, 7.38
mmol) in anhydrous dichloromethane (20 mL) was added
5-fluoro-2-trifluoromethylbenzoyl chloride dropwise at room
temperature. The reaction mixture was stirred at room temperature
for 15 minutes, then diluted with dichloromethane and washed with
water. The organic layer was dried and concentrated in vacuo. The
title compound was obtained in 82% yield (1.365 g) after
purification by column chromatography.
PREPARATION 3
SYNTHESIS OF 3-CYCLOPROPYLPROPYLAMINE
[0251] p-Toluenesulfonyl chloride (7.20 g, 37.8 mmol) was added to
a cooled (0.degree. C.) solution of 2-cyclopropylethanol (4.00 g,
46.4 mmol) in pyridine (10 mL) and dichloromethane (60 mL). The
reaction mixture was stirred at room temperature overnight, then
diluted with ether (200 mL) and washed sequentially with water, 10%
HCl, water and brine and then dried over anhydrous
Na.sub.2SO.sub.4. Toluene-4-sulfonic acid 2-cyclopropylethyl ester
(8.1 g, 89%) was obtained after removal of solvent and used for
next step reaction without further purification.
[0252] A mixture of toluene-4-sulfonic acid 2-cyclopropylethyl
ester (8.1 g, 33.7 mmol), sodium cyanide (5.0 g, 102 mmol) and
tetrabutylammonium iodide (0.5 g) in DMF (30 mL) was heated at
90.degree. C. overnight. The reaction mixture was then cooled to
room temperature, diluted with ether (200 mL), washed with water
and brine, and dried over anhydrous Na.sub.2SO.sub.4.
3-Cyclopropylpropionitrile (3.2 g, 99%) was obtained after removal
of solvent.
[0253] Concentrated sulfuric acid (2.73 mL) was added drop wise to
a vigorously stirred ethereal solution of lithium aluminum hydride
(3.792 g, 99.43 mmol) in 40 mL of ether at 0.degree. C. The
reaction mixture was then warmed to room temperature and stirred
for 1 hour. A solution of 3-cyclopropylpropionitrile (3.085 g,
32.47 mmol) in ether (10 mL) was added drop wise. The resulting
mixture was heated at reflux for 2 hours, then cooled to 0.degree.
C., and subsequently slowly quenched with water. A solution of NaOH
(2 g in 18 mL of H.sub.2O) was added and organic phase was decanted
from the resulting aluminum hydroxide precipitate, which was washed
with ether (3.times.20 mL). All ethereal portions were combined,
and the solvent was distilled off and 3-cyclopropylproylamine was
obtained as a light yellow liquid (2.01 g, 62.5%).
PREPARATION 4
SYNTHESIS OF
[4-(6-AMINOPYRIDAZIN-3-YL)PIPERAZIN-1-YL](2-TRIFLUOROMETHYLPHENYL)METHANO-
NE
[0254] A. To a stirred solution of 1-Boc-piperazine (1.96 g, 10.5
mmol) and diisopropylethylamine (2.714 g, 21 mmol, 3.63 mL) in
dichloromethane (50 mL) was added 2-trifluoromethylbenzoyl chloride
(2.086 g, 10.0 mmol) dropwise. The resulting mixture was stirred at
room temperature for 1 minutes and then quenched with water (25
mL). The organic phase was separated and washed with H.sub.2O,
brine, dried over MgSO.sub.4 and then concentrated in vacuo to
afford product 4-(2-trifluoromethylbenzoyl)-piperazine-1-carboxylic
acid tert-butyl ester as pale yellow solid. Yield 95%, 3.575 g.
[0255] B. A solution of
4-(2-trifluoromethylbenzoyl)piperazine-1-carboxylic acid tert-butyl
ester (10 mmol) in 50 mL of 1:4 mixture of trifluoroacetic acid and
dichloromethane was stirred at room temperature for 10 minutes.
After concentration in vacuo the residue was dissolved in
dichloromethane (100 mL) and washed sequentially with 1 N NaOH (10
mL), H.sub.2O, brine, and then dried over MgSO.sub.4 filtered and
concentrated in vacuo to yield
piperazin-1-yl-(2-trifluoromethylphenyl)-methanone as light yellow
oil. Yield 91%, 2.350 g.
[0256] C. The mixture of 3-amino-6-chloropyridazine (0.6487 g, 5
mmol) and piperazin-1-yl-(2-trifluoromethylphenyl)methanone (1.936
g, 7.5 mmol) in NMP (30 mL) was heated at 150.degree. C. for 24
hours. To the reaction mixture was added 10 mL of 1 N NaOH and 100
mL of dichloromethane, and the aqueous layer was separated and
extracted twice by 100 mL dichloromethane. The combined organic
phase was dried over Na.sub.2SO.sub.4, evaporated to dryness. The
crude compound was purified by flash chromatography to give yellow
solid. Yield 52%, 1.37 g.
PREPARATION 5
SYNTHESIS OF
[4-(3,4-DIAMINOPHENYL)PIPERAZIN-1-YL](2-TRIFLUOROMETHYLPHENYL)METHANONE
[0257] A. A mixture of 5-chloro-2-nitrophenylamine (3.000 g, 17.38
mmol), piperazin-1-yl-(2-trifluoromethylphenyl)methanone (5.360 g,
20.80 mmol) and cesium carbonate (11.32 g, 34.76 mmol) was heated
at 140.degree. C. in anhydrous DMSO (15 mL) for 12 h. The mixture
was cooled and poured over ice water. The solid product obtained
was extracted with ethyl acetate. The organic extracts were
combined, dried over anhydrous sodium sulphate, concentrated in
vacuo. The residue was purified by column chromatography to obtain
the product,
[4-(3-amino-4-nitrophenyl)piperazin-1-yl]-(2-trifluoromethylphenyl)methan-
one, in 79% yield (6.800 g). .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 8.01 (d, 1H, J=9.6 Hz), 7.72 (d, 1H, J=7.9 Hz), 7.62 (t,
1H, J=7.1 Hz), 7.54 (t, 1H, J=7.4 Hz), 7.34 (d, 1H, J=7.3 Hz), 6.22
(dd, 1H, J=2.6, 9.7 Hz), 6.15 (br. s, 2H), 5.94 (d, 1H, J=2.6 Hz),
4.05-3.93 (m, 1H), 3.90-3.80 (m, 1H), 3.50-3.40 (m, 2H), 3.35-3.20
(m, 4H). MS (ES+) m/z 395.1 (M+1).
[0258] B. To a mixture of
[4-(3-amino-4-nitrophenyl)piperazin-1-yl](2-trifluoromethylphenyl)methano-
ne (2.000 g, 5.070 mmol) and Raney Ni (0.5 mL) was added hydrazine
(3 mL). The mixture was allowed to stir at room temperature for 5
h. The mixture was then filtered through celite, washed with ethyl
acetate. The organic extracts were combined, washed with water and
brine, concentrated, and purified by column chromatography to
obtain the title compound in 88% yield (1.830 g). .sup.1H NMR (300
MHz, CDCl.sub.3) 7.70 (d, 1H, J=7.7 Hz), 7.59 (t, 1H, J=7.3 Hz),
7.50 (t, 1H, J=7.4 Hz), 7.33 (d, 1H, J=7.5 Hz), 6.61 (d, 1H, J=8.3
Hz), 6.34 (d, 1H, J=2.5 Hz), 6.28 (dd, 1H, J=2.6, 8.3 Hz), 3.92
(dd, 1H, J=3.4, 6.1 Hz), 3.28 (t, 1H, J=5.1 Hz), 3.12-3.02 (m, 2H),
2.94-2.80 (m, 2H). MS (ES+) m/z 365.2 (M+1).
[0259] The syntheses of compounds of this invention are illustrated
by, but not limited to the following examples.
EXAMPLE 1
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID (3-METHYLBUTYL)AMIDE
[0260] A mixture of
6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid ethyl ester (0.100 g, 0.215 mmol),
isoamylamine (1 mL), and sodium cyanide (0.020 g, 0.408 mmol) was
stirred at room temperature over night. The reaction mixture was
concentrated in vacuo, diluted with ethyl acetate and washed with
water. The organic layer was dried over anhydrous Na.sub.2SO.sub.4,
concentrated. The residue was purified by column chromatography.
The title compound was obtained as a white solid in 85% yield
(0.092 g). .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.13 (s, 1H),
7.74-7.7 (m, 1H), 7.65 (d, J=9.9 Hz, 1H), 7.21-7.16 (m, 1H), 6.86
(d, J=9.9 Hz, 1H), 4.02-3.92 (m, 1H), 3.89-3.79 (m, 1H), 3.62-3.54
(m, 2H), 3.49-3.39 (m, 4H), 3.35-3.28 (m, 2H), 1.74-1.6 (m, 1H),
1.53-1.44 (m, 2H), 0.91 (d, J=6.6 Hz, 6H). .sup.13C NMR (75 MHz,
CDCl.sub.3) .delta. 165.9, 162.5, 162.4, 154.7, 138.4, 137.0,
136.9, 135.6, 129.7, 129.6, 129.5, 126.4, 125.1, 123.3, 122.9,
122.4, 121.4, 118.1, 116.8, 116.5, 114.9, 114.6, 111.8, 46.2, 46.1,
45.6, 41.2, 38.5, 37.3, 25.7, 22.4. MS (ES+) m/z 507 (M+1).
EXAMPLE 1.1
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID PENTYLAMIDE
[0261] Following the procedure as described in Example 1, making
variations only as required to use n-pentylamine in place of
isoamylamine to react with
6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid ethyl ester, the title compound was
obtained as a white solid in 39% yield. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.16 (s, 1H), 7.76-7.66 (m, 2H), 7.33 (s, 1H),
7.27-7.18 (m, 1H), 7.09-7.03 (m, 1H), 6.89 (d, J=9.9 Hz, 1H),
4.05-3.94 (m, 1H), 3.91-3.8 (m, 1H), 3.69-3.54 (m, 2H), 3.15-3.37
(m, 4H), 3.65-3.29 (m, 2H), 1.67-1.55 (m, 2H), 1.42-1.27 (m, 4H),
0.88 (t, J=6.6 Hz, 3H). .sup.13C NMR (75 MHz, CDCl.sub.3) .delta.
165.9, 162.6, 162.3, 154.8, 138.3, 136.9, 135.6, 129.7, 129.6,
129.57, 129.5, 126.3, 125.1, 125.4, 122.9, 121.4, 118.3, 116.8,
116.5, 114.9, 114.6, 111.9, 46.2, 45.6, 41.2, 39.2, 29.4, 29.1,
22.4, 14.0. MS (ES+) m/z 507 (M+1).
EXAMPLE 1.2
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID [2-(4-FLUORO-PHENYL)ETHYL]AMIDE
[0262] Following the procedure as described in Example 1, making
variations only as required to use 2-(4-fluorophenyl)ethylamine in
place of isoamylamine to react with
6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid ethyl ester, the title compound was
obtained as a white solid in 42% yield. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.15 (d, J=3.0 Hz, 1H), 7.76-7.7 (m, 1H), 7.65
(d, J=9.9 Hz, 1H), 7.33 (t, J=6.0 Hz, 1H), 7.27-7.12 (m, 3H),
7.09-7.02 (m, 1H), 7.0-6.91 (m, 2H), 6.87 (d, J=9.9 Hz, 1H),
4.04-3.92 (m, 1H), 3.91-3.79 (m, 1H), 3.71-3.53 (m, 4H), 3.51-3.4
(m, 2H), 3.36-3.28 (m, 2H), 2.88 (t, J=7.2 Hz, 2H). .sup.13C NMR
(75 MHz, CDCl.sub.3) .delta. 165.9, 163.2, 162.4, 160.0, 154.8,
138.1, 135.6, 134.6, 134.58, 130.3, 130.1, 129.7, 129.6, 129.57,
129.5, 126.4, 118.3, 116.8, 116.5, 115.5, 115.2, 114.9, 114.6,
111.9, 46.2, 45.6, 41.3, 40.5, 35.2. MS (ES+) m/z 559 (M+1).
EXAMPLE 1.3
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID 4-FLUOROBENZYLAMIDE
[0263] Following the procedure as described in Example 1, making
variations only as required to use 4-fluorobenzylamine in place of
isoamylamine to react with
6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid ethyl ester, the title compound was
obtained as a white solid in 38% yield. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.19 (d, J=3.0 Hz, 1H), 7.76-7.72 (m, 1H),
7.69-7.6 (m, 2H), 7.35-7.3 (m, 2H), 7.27-7.19 (m, 1H), 7.09-6.94
(m, 3H), 6.89 (d, J=9.9 Hz, 1H), 4.59 (d, J=6.3 Hz, 2H), 4.05-3.94
(m, 1H), 3.91-3.8 (m, 1H), 3.69-3.54 (m, 2H), 3.52-3.43 (m, 2H),
3.38-3.29 (m, 2H). .sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 166.0,
162.6, 162.1, 160.5, 154.8, 137.6, 135.5, 134.1, 134.0, 129.7,
129.6, 126.2, 118.6, 116.8, 116.6, 115.6, 115.3, 114.9, 114.6,
112.2, 46.2, 45.6, 42.5, 41.3. MS (ES+) m/z 508 (M+1).
EXAMPLE 1.4
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID (3-CYCLOPROPYLPROPYL)AMIDE
[0264] Following the procedure as described in Example 1, making
variations only as required to use 3-(cyclopropyl)propylamine in
place of isoamylamine to react with
6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyri-
dazine-2-carboxylic acid ethyl ester, the title compound was
obtained as a white solid in 46% yield (0.079 g). .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 8.15 (d, J=0.6 Hz, 1H), 7.76-7.71 (m, 1H),
7.68 (d, J=9.9 Hz, 1H), 7.30-7.18 (m, 2H), 7.09-7.03 (m, 1H), 6.87
(d, J=9.9 Hz, 1H), 4.04-3.93 (m, 1H), 3.91-3.8 (m, 1H), 3.64-3.54
(m, 2H), 3.51-3.4 (m, 4H), 3.37-3.29 (m, 2H), 1.77-1.65 (m, 2H),
1.32-1.23 (m, 2H), 0.71-0.61 (m 1H), 0.42-0.37 (m, 2H), 0.08-0.03
(m, 2H). .sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 165.9, 162.5,
162.3, 154.7, 138.4, 136.9, 135.6, 129.61, 129.6, 129.5, 126.4,
126.36, 125.0, 123.3, 122.9, 121.4, 118.1, 116.7, 116.5, 114.7,
114.57, 111.8, 46.2, 45.5, 41.2, 38.8, 31.9, 29.7, 10.4, 4.4. MS
(ES+) m/z 519 (M+1).
EXAMPLE 1.5
SYNTHESIS OF
6-[4-(2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRIDAZINE-2--
CARBOXYLIC ACID PENTYLAMIDE
[0265] Following the procedure as described in Example 1, making
variations only as required to use n-pentylamine in place of
isoamylamine to react with
6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2--
carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 56% yield (0.062 g). m.p. 179-180.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.14 (s, 1H), 7.75-7.5 (m, 4H),
7.38-7.27 (s, 2H), 6.89 (d, J=9.6 Hz, 1H), 4.07-3.8 (m, 2H),
3.7-3.51 (m, 2H), 3.5-3.28 (m, 6H), 1.68-1.52 (m, 2H), 1.45-1.28
(m, 4H), 0.89 (t, J=2.1 Hz, 3H). .sup.13C NMR (75 MHz, CDCl.sub.3)
.delta. 167.5, 162.3, 154.8, 138.2, 134.3, 134.2, 132.4, 129.5,
127.1, 126.8, 126.8, 126.2, 125.4, 121.8, 118.2, 111.9, 46.2, 41.2,
39.1, 29.4, 29.1, 22.4, 13.9. MS (ES+) m/z 489.2 (M+1).
EXAMPLE 1.6
SYNTHESIS OF
6-[4-(2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRIDAZINE-2--
CARBOXYLIC ACID BUTYLAMIDE
[0266] Following the procedure as described in Example 1, making
variations only as required to use n-butylamine in place of
isoamylamine to react with
6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2--
carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 72% yield (0.077 g). m.p. 187-189.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.1 (s, 1H), 7.75-7.66 (m, 2H),
7.65-7.5 (m, 2H), 7.48-7.38 (m, 1H), 7.37-7.3 (m, 1H), 6.92 (d,
J=9.6 Hz, 1H), 4.05-3.94 (m, 1H), 3.93-3.82 (m, 1H), 3.69-3.54 (m,
2H), 3.5-3.38 (m, 4H), 3.35-3.28 (m, 2H), 1.65-1.53 (m 2H),
1.47-1.33 (m, 2H), 0.92 (t, J=7.5 Hz, 3H). .sup.13C NMR (75 MHz,
CDCl.sub.3) .delta. 167.5, 161.9, 154.9, 137.7, 135.3, 134.2,
132.4, 129.5, 127.2, 126.8, 126.7, 126.2, 125.4, 121.8, 118.3,
112.3, 46.2, 46.1, 45.6, 41.1, 38.9, 31.7, 20.1, 13.8. MS (ES+) m/z
475.2 (M+1).
EXAMPLE 1.7
SYNTHESIS OF
6-[4-(2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRIDAZINE-2--
CARBOXYLIC ACID (5-CHLOROPYRIDIN-2-YL)AMIDE
[0267] Following the procedure as described in Example 1, making
variations only as required to 5-chloropyridin-2-ylamine in place
of isoamylamine to react with
6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2--
carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 24% yield (0.028 g). m.p. 265-268.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 9.78 (s, 1H), 8.35 (d, J=7.6 Hz,
1H), 8.27-8.25 (2H), 7.81-7.52 (m, 5H), 7.42-7.31 (m, 1H), 6.92 (d,
J=7.6 Hz, 1H), 6.9 (d, J=7.6 Hz, 1H), 4.08-3.97 (m, 1H), 3.95-3.83
(m, 1H), 3.72-3.55 (m, 2H), 3.53-3.43 (m, 2H), 3.37-3.27 (m, 2H).
.sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 167.6, 160.7, 154.9,
149.7, 146.7, 137.8, 137.3, 135.8, 134.2, 132.4, 129.5, 127.2,
127.2, 126.9, 126.8, 126.7, 126.5, 125.4, 118.9, 114.5, 112.3,
46.2, 46.18, 45.6, 41.2. MS (ES+) m/z 530.1 (M+1).
EXAMPLE 1.8
SYNTHESIS OF
6-[4-(2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRIDAZINE-2--
CARBOXYLIC ACID 4-FLUOROBENZYLAMIDE
[0268] Following the procedure as described in Example 1, making
variations only as required to 4-fluorobenzylamine in place of
isoamylamine to react with
6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2--
carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 30% yield (0.035 g). m.p. 205-207.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.18 (s, 1H), 7.77-7.5 (m, 5H),
7.38-7.27 (m, 3H), 7.03-6.94 (m, 2H), 6.9 (d, J=9.6 Hz, 1H), 4.58
(d, J=6 Hz, 2H), 4.06-3.94 (m, 1H), 3.93-3.81 (m, 1H), 3.69-3.54
(m, 2H), 3.52-3.42 (m, 2H), 3.36-3.27 (m, 2H). .sup.13C NMR (75
MHz, CDCl.sub.3) .delta. 167.6, 163.7, 162.3, 160.5, 154.8, 137.8,
135.7, 134.2, 132.4, 129.6, 129.5, 126.9, 126.8, 126.7, 125.3,
124.4, 121.8, 118.4, 115.6, 115.3, 112.0, 46.2, 46.2, 45.6, 42.4,
41.2. MS (ES+) m/z 527.2 (M+1).
EXAMPLE 1.9
SYNTHESIS OF
6-[4-(2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]-IMIDAZO[1,2-B]PYRIDAZINE-2-
-CARBOXYLIC ACID (4-FLUOROPHENYL)AMIDE
[0269] Following the procedure as described in Example 1, making
variations only as required to 4-fluoroaniline in place of
isoamylamine to react with
6-[4-(2-trifluoromethyl-benzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2-
-carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 57% yield (0.065 g). m.p. 115-117.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 9.1 (s, 1H), 8.22 (s, 1H),
7.74-7.5 (m, 6H), 7.35-7.33 (m, 1H), 7.08-6.95 (m, 2H), 6.9 (d,
J=7.6 Hz, 1H), 4.06-3.94 (m, 1H), 3.93-3.81 (m, 1H), 3.7-3.53 (m,
2H), 3.51-3.4 (m, 2H), 3.6-3.27 (m, 2H). .sup.13C NMR (75 MHz,
CDCl.sub.3) .delta. 167.6, 160.8, 160.2, 157.6, 154.9, 137.8,
135.7, 134.3, 134.2, 134.1, 134.0, 132.4, 129.5, 127.2, 126.9,
126.8, 126.7, 126.5, 125.4, 121.2, 121.1, 118.7, 115.8, 115.5,
112.2, 46.2, 46.1, 45.6, 41.2. MS (ES+) m/z 513.3 (M+1).
EXAMPLE 1.10
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID HEXYLAMIDE
[0270] Following the procedure as described in Example 1, making
variations only as required to n-hexylamine in place of
isoamylamine to react with
6-[4-(2-trifluoromethyl-benzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2-
-carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 78% yield (0.090 g). .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.12 (s, 1H), 7.73-7.61 (m, 2H), 7.22-7.16 (m,
2H), 7.08-7.02 (m, 1H), 6.85 (d, J=10.2 Hz, 1H), 4.01-3.78 (m, 2H),
3.65-3.26 (m, 8H), 1.62-1.51 (m, 2H), 1.4-1.18 (m, 6H), 0.83 (t,
J=6.6 Hz, 3H). .sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 165.9,
162.6, 162.3, 154.8, 138.3, 136.9, 135.6, 129.7, 129.6, 129.57,
129.5, 126.3, 125.1, 125.4, 122.9, 121.4, 118.3, 116.8, 116.5,
114.9, 114.6, 111.9, 46.2 (2 peaks), 45.6, 41.2, 39.2, 29.4, 29.1,
22.4, 14.0. MS (ES+) m/z 521.2 (M+1).
EXAMPLE 1.11
SYNTHESIS OF
6-[4-(5-FLUORO-2-TRIFLUOROMETHYLBENZOYL)PIPERAZIN-1-YL]IMIDAZO[1,2-B]PYRI-
DAZINE-2-CARBOXYLIC ACID BUTYLAMIDE
[0271] Following the procedure as described in Example 1, making
variations only as required to n-butylamine in place of
isoamylamine to react with
6-[4-(2-trifluoromethyl-benzoyl)piperazin-1-yl]imidazo[1,2-b]pyridazine-2-
-carboxylic acid ethyl ester, the title compound was obtained as a
white solid in 75% yield (0.082 g). .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.11 (s, 1H), 7.73-7.66 (m, 1H), 7.62 (d, J=9.3
Hz, 1H), 7.25-7.14 (m, 2H), 7.06-7.0 (m, 1H), 6.84 (d, J=9.3 Hz,
1H), 3.85-3.88 (m, 1H), 3.87-3.76 (m, 1H), 3.63-3.25 (m, 8H),
1.6-1.48 (m, 2H), 1.43-1.29 (m, 2H), 0.88 (t, J=7.2 Hz, 3H).
.sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 165.9, 162.6, 162.3,
154.7, 138.4, 136.9, 136.8, 135.6, 129.7, 129.6, 129.57, 129.5,
126.3, 125.1, 125.4, 122.9, 121.4, 118.3, 116.8, 116.5, 114.9,
114.6, 111.9, 46.2, 45.6, 38.8, 38.3, 31.8, 20.1, 13.7. MS (ES+)
m/z 493.6 (M+1).
EXAMPLE 2
SYNTHESIS OF
[4-(2-ETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PIPERAZIN-1-YL](2-TRIFLUOROMETHYL-
PHENYL)METHANONE
[0272] A mixture of
[4-(6-aminopyridazin-3-yl)piperazin-1-yl](2-trifluoromethylphenyl)-methan-
one (0.120 g, 0.342 mmol), 1-bromobutan-2-one (0.077 g, 0.512 mmol)
and sodium bicarbonate (0.016 g) in ethanol was refluxed over
night. The reaction mixture was concentrated in vacuo, then diluted
with 10 mL of water, extracted with ethyl acetate. The organic
layer was dried and concentrated. The residue was purified by
column chromatography. The title compound was obtained as a white
solid in 69% yield (0.095 g). .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 7.73-7.47 (m, 4H), 7.43 (s, 1H), 7.33 (d, J=7.5 Hz, 1H),
6.71 (d, J=7.5 Hz, 1H), 4.02-3.82 (m, 2H), 3.58-3.5 (m, 2H),
3.4-3.25 (m, 4H), 2.78 (q, 2H), 1.29 (m, J=7.5 Hz, 3H). .sup.13C
NMR (75 MHz, CDCl.sub.3) .delta. 167.5, 154.4, 148.1, 135.7,
134.44, 134.41, 132.3, 129.4, 127.2, 126.9, 126.8, 126.7, 125.4,
125.34, 121.8, 113.1, 109.4, 46.6, 46.4, 46.2, 41.2, 22.4, 13.5. MS
(ES+) m/z 404 (M+1).
EXAMPLE 2.1
SYNTHESIS OF
[4-(2-PENTYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PIPERAZIN-1-YL](2-TRIFLUOROMETHY-
LPHENYL) METHANONE
[0273] Following the procedure as described in Example 2, making
variations only as required to 1-bromoheptan-2-one in place of
1-bromobutan-2-one to react with
[4-(6-aminopyridazin-3-yl)piperazin-1-yl](2-trifluoromethylphenyl)methano-
ne, the title compound was obtained as a white solid in 62% yield.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.71-7.69 (m, 1H),
7.64-7.49 (m, 3H), 7.42 (s, 1H), 7.34-7.32 (m, 1H), 6.7 (d, J=9.9
Hz, 1H), 4.01-3.83 (m, 2H), 3.57-3.48 (m, 2H), 3.37-3.27 (m, 4H),
2.73-2.68 (m, 2H), 1.75-1.65 (m, 2H), 1.4-1.25 (m, 4H), 0.91 (t,
J=6.9 Hz, 3H). .sup.13C NMR (75 MHz, CDCl.sub.3) 6167.5, 154.3,
146.8, 135.7, 134.4, 132.3, 129.4, 127.1, 126.8, 126.7, 126.6,
125.4, 125.3, 121.8, 113.6, 109.3, 46.5, 46.4, 46.2, 41.1, 31.5,
29.1, 29.07, 22.5, 14.0. MS (ES+) m/z 446.2 (M+1).
EXAMPLE 2.2
SYNTHESIS OF
[4-(2-BUTYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PIPERAZIN-1-YL]-(2-TRIFLUOROMETHY-
LPHENYL)METHANONE
[0274] Following the procedure as described in Example 2, making
variations only as required to use 1-bromohexan-2-one in place of
1-bromobutan-2-one to react with
[4-(6-aminopyridazin-3-yl)piperazin-1-yl](2-trifluoromethylphenyl)methano-
ne, the title compound was obtained as a white solid in 42% yield.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.72-7.48 (m, 4H), 7.43
(s, 1H), 7.35-7.32 (m, 1H), 6.71 (d, J=9.9 Hz, 1H), 4.02-3.83 (m,
2H), 3.53 (m, 2H), 3.37-3.3 (m, 4H), 2.74-2.69 (m, 2H), 1.76-1.61
(m, 2H), 1.48-1.3 (m, 2H), 0.91 (t, J=7.2 Hz, 3H). .sup.13C NMR (75
MHz, CDCl.sub.3) .delta. 167.4, 154.3, 146.8, 135.7, 134.4, 132.3,
129.4, 127.0, 126.8, 126.76, 126.7, 126.6, 126.2, 125.4, 125.3,
121.8, 113.6, 109.3, 46.5, 46.3, 46.2, 41.1, 31.5, 28.8, 22.4,
13.9. MS (ES+) m/z 432.3 (M+1).
EXAMPLE 3
SYNTHESIS OF
[4-(2-PROPYL-1H-BENZOIMIDAZOL-5-YL)PIPERAZIN-1-YL](2-TRIFLUOROMETHYLPHENY-
L)METHANONE
[0275] A mixture of
[4-(3,4-diaminophenyl)piperazin-1-yl](2-trifluoromethylphenyl)-methanone
(0.500 g, 1.370 mmol) and butyric acid (0.180 g, 2.040 mmol) was
heated to reflux in POCl.sub.3 for 12 h. The mixture was cooled to
room temperature and then concentrated. The black syrup was poured
over 10% Na.sub.2CO.sub.3 solution, then extracted with ethyl
acetate, washed with water and brine. The solvent was removed in
vacuo and the residue was purified by column chromatography to
yield the title compound as a yellow syrup in 52% yield (0.115 g).
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.90 (br., s, 1H), 7.69
(d, J=7.6 Hz, 1H), 7.62-7.42 (m, 2H), 7.36 (d, J=9.2 Hz, 2H), 6.98
(s, 1H), 6.87 (dd, J=2.0, 8.7 Hz, 1H), 4.01-3.91 (m, 2H), 3.33 (t,
J=4.8 Hz, 2H), 3.15 (t, J=4.8 Hz, 2H), 3.05-2.95 (m, 2H), 2.79 (t,
J=7.4 Hz, 2H), 1.85-1.70 (m, 2H), 0.90 (t, J=7.3 Hz, 3H). .sup.13C
NMR (75 MHz, CDCl.sub.3) .delta. 167.5, 155.4, 147.2, 134.5, 134.5,
132.3, 129.3, 127.2, 127.0, 126.8, 126.8, 126.7, 126.7, 126.6,
126.2, 125.4, 121.8, 114.7, 102.5, 102.4, 102.3, 51.4, 51.2, 47.3,
41.9, 31.1, 21.6, 13.8. MS (ES+) m/z 417.1 (M+1).
EXAMPLE 3.1
SYNTHESIS OF
[4-(2-PENTYL-1H-BENZOIMIDAZOL-5-YL)PIPERAZIN-1-YL](2-TRIFLUOROMETHYLPHENY-
L)METHANONE
[0276] Following the procedure as described in Example 3, making
variations only as required to use n-hexanoic acid in place of
butyric acid to react with
[4-(3,4-diaminophenyl)piperazin-1-yl](2-trifluoromethylphenyl)methanone,
the title compound was obtained as a yellow syrup in 57% yield
(0.347 g). .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.8 (br., s,
1H), 7.70 (d, J=7.7 Hz, 1H), 7.64-7.45 (m, 2H), 7.36 (d, J=8.7 Hz,
1H), 6.99 (s, 1H), 6.87 (dd, J=1.9, 8.7 Hz, 1H), 4.00-3.91 (m, 2H),
3.33 (t, J=4.8 Hz, 2H), 3.15 (t, J=5.1 Hz, 2H), 3.05-2.95 (m, 2H),
2.82 (t, J=7.7 Hz, 2H), 1.85-1.70 (m, 2H), 1.33-1.16 (m, 4H), 0.79
(t, J=7.0 Hz, 3H). .sup.13C NMR (75 MHz, CDCl.sub.3) .delta. 167.5,
155.3, 147.4, 138.4, 134.5, 134.0, 132.3, 129.3, 127.2, 127.1,
126.8, 126.8, 126.7, 126.6, 125.4, 121.8, 115.4, 115.3, 114.9,
102.3, 51.3, 51.1, 47.3, 41.9, 31.4, 29.1, 27.9, 22.3, 13.9. MS
(ES+) m/z 445.2 (M+1).
EXAMPLE 4
MEASURING STEAROYL-COA DESATURASE INHIBITION ACTIVITY OF A TEST
COMPOUND USING MOUSE LIVER MICROSOMES
[0277] The identification of compounds of the invention as SCD
inhibitors was readily accomplished using the SCD enzymes and
microsomal assay procedure described in Brownlie et al, PCT
published patent application, WO 01/62954.
Preparation of Mouse Liver Microsomes:
[0278] Male ICR mice, on a high-carbohydrate, low fat diet, under
light halothane (15% in mineral oil) anesthesia are sacrificed by
exsanguination during periods of high enzyme activity. Livers are
immediately rinsed with cold 0.9% NaCl solution, weighed and minced
with scissors. All procedures are performed at 4.degree. C. unless
specified otherwise. Livers are homogenized in a solution (1:3 w/v)
containing 0.25 M sucrose, 62 mM potassium phosphate buffer (pH
7.0), 0.15 M KCl, 1.5 mM N-acetyleysteine, 5 mM MgCl.sub.2, and 0.1
mM EDTA using 4 strokes of a Potter-Elvehjem tissue homogenizer.
The homogenate is centrifuged at 10,400.times.g for 20 min to
eliminate mitochondria and cellular debris. The supernatant is
filtered through a 3-layer cheesecloth and centrifuged at
105,000.times.g for 60 min. The microsomal pellet is gently
resuspended in the same homogenization solution with a small
glass/teflon homogenizer and stored at -70.degree. C. The absence
of mitochondrial contamination is enzymatically assessed. The
protein concentration is measured using bovine serum albumin as the
standard.
Incubation of Mouse Liver Microsomes with Test Compounds:
[0279] Reactions are started by adding 2 mg of microsomal protein
to pre-incubated tubes containing 0.20 .mu.Ci of the substrate
fatty acid (1-.sup.14C palmitic acid) at a final concentration of
33.3 .mu.M in 1.5 ml of homogenization solution, containing 42 mM
NaF, 0.33 mM niacinamide, 1.6 mM ATP, 1.0 mM NADH, 0.1 mM coenzyme
A and a 10 .mu.M concentration of test compound. The tubes are
vortexed vigorously and after 15 min incubation in a shaking water
bath (37.degree. C.), the reactions are stopped and fatty acids are
analyzed.
[0280] Fatty acids are analyzed as follows: The reaction mixture is
saponified with 10% KOH to obtain free fatty acids which are
further methylated using BF.sub.3 in methanol. The fatty acid
methyl esters are analyzed by high performance liquid
chromatography (HPLC) using a Hewlett Packard 1090, Series II
chromatograph equipped with a diode array detector set at 205 nm, a
radioisotope detector (Model 171, Beckman, Calif.) with a solid
scintillation cartridge (97% efficiency for .sup.14C-detection) and
a reverse-phase ODS (C-18) Beckman column (250 mm.times.4.6 mm
i.d.; 5 .mu.m particle size) attached to a pre-column with a
.mu.Bondapak C-18 (Beckman) insert. Fatty acid methyl esters are
separated isocratically with acetonitrile/water (95:5 v:v) at a
flow rate of 1 mL/min and are identified by comparison with
authentic standards. Alternatively, fatty acid methyl esters may be
analyzed by capillary column gas-chromatography (GC) or Thin Layer
Chromatography (TLC).
[0281] Those skilled in the art are aware of a variety of
modifications to this assay that can be useful for measuring
inhibition of stearoyl-CoA desaturase activity in microsomes by
test compounds.
[0282] Representative compounds of the invention showed activity as
inhibitors of SCD when tested in this assay. The activity was
defined in terms of % SCD enzyme activity remaining at the desired
concentration of the test compound.
[0283] All of the U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification and/or listed in the Application Data Sheet are
incorporated herein by reference, in their entirety.
[0284] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
* * * * *